YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?

1. Introduction

A critical step in translational medicine for personalizing treatment is to identify new diagnostic, prognostic and predictive cancer biomarkers. There has therefore been an increasing focus on identification of novel cancer biomarkers. Tumor molecular profiling is now included in many clinical trials [ 1 ]. New biomarkers have the potential to identify cancer patients at an early stage, select patients who are most likely to benefit from therapy and to guide the development of more effective agents. New biomarkers will help to personalize standard medicine for patients with cancer.

Tumor molecular heterogeneity is a major reason that patients with cancer with a similar tumor histology and clinical stage can have a very different clinical outcome and response to treatment with chemotherapy and biologics (e.g., antibodies against the epidermal growth factor receptors and insulin growth factor receptor). A new generation of molecular technologies, including genomic, proteomic and metabolomic mapping, holds the promise of translating into practice the use of biomarker panels for increased diagnostic and therapeutic sensitivity and specificity.

A protein biomarker is, in general defined, as a measurable protein that is an indicator of normal biologic processes, pathogenic processes, and/or response to therapeutic or other interventions. The definition does not include specific technologies except that the biomarker should be possible to measure objectively [ 2 ] ( http://www.fda.gov/cder/guidance/6400fnl.htm/ , September 2004). Protein cancer biomarkers should have an association with cancer and an application in clinical detection (screening and early diagnosis) and management (prognosis, treatment response and monitoring). Prognostic biomarkers can forecast survival independent of the treatment administered. Predictive biomarkers should identify cancer patients who are likely to have increased sensitivity or resistance to a given therapy reflected in either tumor shrinkage or growth and prolonged survival or decreased survival. Biomarkers can be both prognostic and predictive. It is most likely that biomarkers should be combined in panels of biomarkers for optimal clinical use, since most biomarkers will probably individually lack optimal sensitivity and specificity. This review focuses on plasma YKL-40 as a potential new cancer biomarker.

2. YKL-40 Gene and Protein

In 1997, the human gene encoding the protein YKL-40 was isolated [ 3 ]. It is located on chromosome 1q32.1, has a size of 7948 base pairs and consists of 10 exons [ 3 , 4 ]. Two splice forms of the YKL-40 gene are reported; isoform 1 contains exon 1-10 and in isoform 2 exon 8 is spliced out [ 5 ].

YKL-40 [ 6 ] is also named human cartilage glycoprotein-39 (HC-gp39) [ 7 ], 38-kDa heparin-binding glycoprotein (gp38k) [ 8 ], chitinase-3-like-1 (CHI3L1) [ 3 ], and chondrex [ 9 ]. It is a glycoprotein and a member of "Family 18 chitolectins" [ 10 , 11 , 12 ] and “Mammalian chitinase like proteins”. YKL-40 is described in human [ 7 ], chimpanzee, pig [ 8 ], cow, goat [ 13 ], sheep, guinea pig [ 14 ], rat and mouse [ 15 ] and is phylogenetically highly conserved. The fruit fly Drosophila melanogaster [ 16 , 17 ], the mosquito Anopheles gambiae , the zebra fish Danio rerio , the pacific oyster Crassostrea gigas [ 18 ] and the nematode Caenorhabditis elegans have putative YKL-40-like proteins (National Center for Biotechnology Information (NCBI)). The YKL-40 protein contains a single polypeptide chain of 383 amino acids and has a molecular mass of 40 kDa [ 7 ] and an isoelectric point of 7.6 [ 19 ]. The crystallographic structure for human YKL-40 [ 20 , 21 ] displays the typical fold of family 18 glycosyl hydrolases [ 22 ].

3. YKL-40 in Healthy Subjects

3.1. Tissue

We have found that YKL-40 is produced by human embryonic stem cells and their progenitors, Figure 1 A-C [ 23 ]. YKL-40 mRNA and protein expressions are also strongly expressed in all germ layers of human embryos and in human fetal tissues of ecto-, meso- and endoderm layers [ 5 ]. At the cellular level YKL-40 protein expression is high in embryonic and fetal tissues characterized by rapid proliferation and marked differentiation, and in tissues undergoing morphogenetic changes [ 5 ]. In adult normal tissue high YKL-40 expression is observed in cells with high cellular activity [ 24 ].

3.2. Plasma Concentrations of YKL-40 in Healthy Subjects

To be clinically useful determination of plasma YKL-40 must use specific, sensitive, cheap and fast methods allowing reliable measurements, optimal capability for high throughput tests, prompt turnaround time, and reasonable cost. The most used commercial enzyme-linked immunoassay (ELISA) to determine plasma YKL-40 is from Quidel (Santa Clara, CA, USA) [ 9 ]. It uses streptavidin-coated microplate wells, a biotinylated-Fab monoclonal mouse antibody against human YKL-40 (capture antibody) and an alkaline phosphatase-labeled polyclonal rabbit antibody against human YKL-40 (detection antibody). The sensitivity is 20 µg/L, detection limit 8 µg/L, and recovery 102%. The intra-assay coefficients of variations are 5% (at 40 µg/L), 4% (at 104 µg/L), and 4% (at 155 µg/L). The inter-assay coefficient of variation is <6% (personal observations). An ELISA from R&D Systems (Abingdon, Oxon, United Kingdom) is also become commercial available, but there are no publications regarding this ELISA.

Plasma levels of YKL-40 in both sexes are highly (p < 0.001) correlated with age [ 9 , 25 , 26 , 27 ]. Thus, the normal, age-corrected, upper level of plasma YKL-40 is an important factor to consider in clinical studies of patients with cancer using plasma YKL-40 as a potential biomarker. There is no difference in plasma YKL-40 between the two sexes and the median plasma YKL-40 level in healthy subjects is ~40 µg/L [ 9 , 25 , 26 ]. In these three studies used to determine the normal plasma YKL-40 levels, there were no follow-up of the subjects after the blood samples were collected for plasma YKL-40 determination. This is an important problem, since it has been reported that plasma YKL-40 can be elevated years before a subject has clinical signs of cancer [ 27 ]. We have therefore determined plasma YKL-40 in a large group of 3610 healthy adults, aged 20–95 years, from the Danish general population, the Copenhagen City Heart Study. These subjects had no known disease at time of blood sampling in 1991–1994 and remained healthy during the 16 years follow-up period (Bojesen, S.E., manuscript in preparation). We found that plasma YKL-40 increased significantly with age in both sexes, and was not associated with body mass index (BMI) and plasma C-reactive protein (CRP) levels. Furthermore, plasma YKL-40 was stable in subjects that remain healthy during a 10 years period. Based on the results from this large study of truly healthy subjects we suggest that an elevated plasma YKL-40 is defined as an age-corrected plasma YKL-40 concentration higher than the 95 th or the 97 th percentile of plasma YKL-40 in healthy age-matched subjects.

Recently, a new technique to determine plasma YKL-40 has been developed using the proximity ligation assay (PLA) [ 28 , 29 ]. This method employs pairs of antibodies coupled to DNA oligonucleotides such that when the antibody pairs bind to the target protein, the local concentration of DNA oligonucleotides increases to allow for enzymatic ligation of the two strands. The resulting amplicons are unique for each specific protein detected and can be measured in a highly quantitative manner by real-time quantitative real time polymerase chain reaction (qPCR). The PLA technique can be multiplexed for simultaneous detection of multiple proteins, is highly sensitive with limited background, and requires only 10 µL of plasma. This technology has been piloted in small scale biomarker studies where YKL-40 is one of 83 biomarkers [ 28 , 29 ]. However, more validation studies are needed and this multiplex PLA system is not yet commercially available.

A standard operating procedure must be used when handling blood samples for determination of plasma YKL-40. The time interval between drawing of blood and centrifugation of blood stored at room temperature must be less than eight hours for EDTA plasma samples and less than three hours for serum. Otherwise, significant and non-disease related elevations in plasma YKL-40 are found. If the blood is stored at 4 °C before centrifugation YKL-40 concentrations are stable in EDTA plasma for 72 hours and in serum for 24 hours [ 30 ]. Degranulation of neutrophils will release YKL-40 from the specific granules, and neutrophils are the main source of this time dependent increase in YKL-40 concentrations in serum and EDTA plasma. After the blood cells are removed, YKL-40 is stable in plasma stored up to five days at room temperature [ 30 ], up to nine days at 4 °C [ 9 ], and at −80 °C for at least 14 years (personal observation). Repetitive freezing and thawing of plasma samples up to nine times have no effect on plasma YKL-40 levels [ 9 , 30 , 31 ]. The YKL-40 serum/EDTA plasma ratio is 1.4, and the YKL-40 levels in corresponding serum and EDTA plasma samples are correlated (rho = 0.98, p < 0.001) [ 30 , 31 ]. The slightly higher levels of YKL-40 in serum compared to EDTA plasma is probably caused by release of YKL-40 from activated neutrophils during the coagulation process. In this review, there will be no discrimination between YKL-40 levels in EDTA plasma and serum samples, since the levels of YKL-40 in the patients were related to EDTA plasma or serum concentrations of YKL-40 in healthy subjects.

Plasma YKL-40 levels are relatively stable in healthy subjects during a day, a month, a year and during a period of three years. The within subject coefficient of variations including variation over time and inter-assay were 28.8% and 30.2% over a period of two and three years, and the intra-class correlation coefficients were 72.4% and 72.2% indicating reasonable reliability of plasma YKL-40 measurements. An estimated variation in plasma YKL-40 within healthy subjects including inter-assay variation suggests that an increase of more than 109% or a decrease of more than 52% in plasma YKL-40 could be considered as significant and not only a reflection of pre-analytical conditions, methodological and normal biologic variability [ 26 ]. Furthermore, plasma YKL-40 was stable in 929 healthy subjects from the Danish general population, who had plasma YKL-40 measured twice in blood samples collected with 10 years interval (Bojesen, S.E., manuscript in preparation).

4. YKL-40 in Different Types of Cancer

The pivotal criterion with regard to the potential clinical value of a candidate cancer biomarker is the consistency and strenght of the association between the biomarker and the outcome of the cancer of interest, and the extent to which it is an improvement on either adding to or replacing established tools. The use of plasma YKL-40 has not received Food and Drug Administration (FDA) approval for use as a biomarker in patients with cancer. It is not known whether determination of plasma YKL-40 can be useful in clinical practice, e.g., allowing clinicians to use elevated plasma YKL-40 in risk assessment of healthy subjects and patients, in treatment selection and in monitoring disease relapse or progression during and after treatment.

In the next sections we will describe what has been published since the first publication 15 years ago describing plasma YKL-40 as a potential marker of prognosis in patients with recurrent breast cancer [ 32 ]. In the beginning there was little interest in plasma YKL-40 as a biomarker, but during the last few years the number of publications regarding YKL-40 has increased markedly ( Figure 2 ).

4.1. Adenocarcinoma

4.1.1. Tissue

YKL-40 mRNA and protein expression are found in cancer tissue from breast, colon, liver, lung, ovary, pancreas, prostate, gastric and uterus [ 33 ], and in tumor associated macrophages [ 33 , 34 , 35 , 36 , 37 , 38 ], Figure 3 B,C,D,H,I. There are no reports of adenocarcinoma cell lines producing high levels of YKL-40 in vitro . This is in contrast to the very high YKL-40 production in vitro by the human osteosarcoma cell line MG63 [ 6 ]. Microarray gene analyses have shown that YKL-40 is overexpressed compared to normal tissue in human papillary thyroid carcinoma [ 39 ]. In breast cancer YKL-40 protein expression is high compared to normal breast tissue Figure 3 A, B [ 40 , 41 , 42 , 43 ] and was a predictor of short disease-free survival in a small study [ 40 ]. However, this could not be confirmed in a large study of patients with primary breast cancer [ 43 ]. In colorectal, gastric, hepatocellular, pancreatic, non-small cell lung and ovarian adenocarcinoma YKL-40 protein expression is high compared to normal tissues [ 36 , 37 , 38 , 44 ] as illustrated in Figure 3 C, D, H, I. In colorectal cancer (personal observation), non-small cell lung cancer [ 37 ], and ovarian cancer [ 36 ] the YKL-40 protein expression scores were not associated with prognosis. Whereas in gastric cancer high YKL-40 protein expression was an independent biomarker of short survival and associated with tumor invasion, lymph node metastasis and activation of Akt [ 38 ].

4.1.2. Screening

Plasma YKL-40 has been determined in a large prospective cohort study of 8899 subjects (aged 20–95 years) from the Danish general population, the Copenhagen City Heart Study, followed for 11 years for cancer incidence and for 14 years for death. Very high plasma YKL-40 levels, i.e. , in the 96–100% percentile category, in subjects without known cancer predicted a 3.4 fold increased risk of gastrointestinal cancer (multifactorially adjusted for sex, age, smoking history, alcohol intake, and body mass index). Furthermore, high plasma YKL-40 levels predicted an absolute 10-year risk of gastrointestinal cancer of 14% in women and 20% in men and who were >70 years and smokers [ 27 ]. Mechanistically, this increased risk of gastrointestinal cancer may be explained either by the fact that cancer cells and tumor associated macrophages produce YKL-40, that elevated YKL-40 cause gastrointestinal cancer, or that a common factor like chronic inflammation cause both elevated plasma YKL-40 and cancer. An association between a biomarker and a disease may represent a causal relationship (causation), an increase in the biomarker as a consequence of the disease or its treatment (reverse causation), or an association that is spurious because both the biomarker and the disease are affected independently by another known or unknown factor (confounding) [ 45 ]. Studies are ongoing in relation to YKL-40 genotyping in this large cohort of 8899 subjects and we want to test the following hypotheses: (1) genetic variants in the YKL-40 gene are associated to plasma levels of YKL-40 in the general population; (2) genetic variants in the YKL-40 gene are a risk factor for future cancer; and (3) genetic variants in the YKL-40 gene are associated to certain types of cancer.

Plasma YKL-40 has also been determined in a prospective, population based study of 4987 subjects (aged 18–97 years) referred to endoscopy due to symptoms or other risk factors for colorectal cancer. 303 subjects were diagnosed with colorectal cancer [ 46 ]. Multivariate logistic regression analysis including plasma YKL-40, carcinoembryonic (CEA), age, sex, BMI, smoking, alcohol intake and co-morbidity demonstrated that plasma YKL-40 independently predicted colorectal cancer [ 47 ].

Recently, it was reported that plasma YKL-40, carbohydrate antigen 19-9 (CA-19-9) and osteopontin in combination had superior sensitivity for detection of locally advanced, stage II/III pancreatic cancer compared to CA 19-9 alone (93% vs. 80%) [ 29 ]. Studies are therefore ongoing to evaluate if plasma YKL-40 in combination with a panel of other biomarkers can be of value for detection of pancreatic cancer at an early stage.

These studies suggest that plasma YKL-40 may be useful in the assessment of early detection of gastrointestinal cancer, but the results should be validated. It is also unknown if plasma YKL-40 could be used for risk assessment of other types of adenocarcinoma.

4.1.3. Prevalence of High Plasma YKL-40 Levels

Plasma YKL-40 is elevated, defined as higher than the age-adjusted 95 th percentile of plasma YKL-40 in healthy subjects, in some patients with primary or advanced adenocarcinoma of the breast [ 33 , 48 , 49 , 50 , 51 ], colorectal [ 52 , 53 , 54 ], endometrial [ 55 ], lung [ 56 ], pancreas [ 28 , 29 , 57 ], prostate [ 58 , 59 , 60 ], ovary [ 36 , 61 , 62 , 63 , 64 , 65 ] and cervix [ 66 ]. Highest plasma YKL-40 levels are found in patients with advanced cancer. The percentage of patients with elevated plasma YKL-40 was highest in patients with metastatic pancreatic and ovarian adenocarcinoma, ~80% of these patients had elevated plasma YKL-40, Figure 4 . These types of cancer are characterized by a very dismal prognosis.

4.1.4. Prognosis

High pre-treatment plasma YKL-40 is an independent prognostic biomarker of short overall survival in patients with different types of adenocarcinoma, Table 1 . This was found in patients with localized or advanced breast [ 32 , 48 , 49 , 50 , 51 ], colorectal [ 52 , 53 , 54 ], endometrial [ 55 ], non-small cell lung [ 56 ], ovary [ 36 , 61 , 62 , 63 , 64 ], cervix [ 66 ] and prostate [ 58 , 59 , 60 ] adenocarcinoma both at time of first cancer diagnosis and at time of relapse. Plasma YKL-40 was independent of other routinely used biomarkers ( i.e. , estrogen receptor status, KRAS mutation status, serum levels of human epidermal growth factor receptor 2 (HER2), CEA, carbohydrate antigen (CA) 125, prostate-specific antigen (PSA) and lactate dehydrogenase (LDH) and clinical parameters ( i.e. , age, performance status, tumor stage, histology) when tested in multivariate Cox analysis [ 32 , 36 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 66 ]. In many of these studies, but not all, pre-treatment plasma YKL-40 was also a prognostic biomarker of recurrence- or progression-free interval. Plasma YKL-40 may therefore provide additional information of prognosis in patients with different types of adenocarcinoma.

4.1.5. Treatment Response

Few studies have evaluated if pre-treatment plasma YKL-40 is a predictor of treatment response. Plasma YKL-40 decreased in patients after curative operation for colorectal cancer, whereas patients with elevated plasma YKL-40 six months after operation had shorter recurrence-free interval and overall survival [ 53 ]. In patients with first recurrence of breast cancer high plasma YKL-40 predicted less responsiveness to anthracycline therapy [ 48 ], and high plasma YKL-40 was a predictor of second-line chemo resistance in patients with ovarian cancer [ 64 ]. Pre-treatment plasma YKL-40 was an independent prognostic biomarker in patients with metastatic prostate cancer treated with endocrine therapy [ 58 ]. Recently, we have found that high plasma YKL-40 in patients with metastatic colorectal cancer before 3. line treatment with cetuximab and irinotecan was associated with short progression free survival and short overall survival, independent of KRAS status [ 54 ].

4.1.6. Monitoring

Early changes in biomarkers are investigated as potential predictors of response. They may be useful in early identification of patients unlikely to benefit, so as to spare them ineffective and potentially toxic treatment. Furthermore, monitoring plasma biomarkers in cancer patients without evidence of disease might allow for earlier detection of recurrence. There is limited information regarding changes in plasma YKL-40 during treatment of cancer patients. Increases in plasma YKL-40 during follow-up after curative resection of colorectal cancer was related to increased risk of recurrence and death [ 53 ]. During treatment of patients with metastatic colorectal cancer with 3. line cetuximab and irinotecan plasma YKL-40 as well as the ratio of updated YKL-40 levels compared to pre-treatment levels were associated with progression free survival and overall survival, and high YKL-40 values indicated poor prognosis [ 54 ]. In patients with metastatic prostate cancer treated with endocrine therapy, high plasma YKL-40 during treatment was related to short survival [ 59 ]. In a small study of patients with locally advanced pancreatic cancer increased plasma YKL-40, compared to pre-treatment levels, four to six weeks after the end of radiochemotherapy, was associated with short overall survival [ 57 ]. In patients with metastatic pancreatic cancer, an increase in plasma YKL-40 four weeks after start of chemoradiotherapy was also associated with short survival [ 57 ].

4.2. Squamous Cell Carcinoma

4.2.1. Tissue

YKL-40 protein expression is high compared to normal tissue in head and neck, cervix and anal squamous cell carcinoma [ 66 , 67 , 68 , 69 ], Figure 3 E,F. YKL-40 protein expression was not associated with prognosis in head and neck squamous cell carcinoma [ 68 ], and has not been evaluated in cervix squamous cell carcinoma. In anal squamous cell carcinoma expression of YKL-40 was highest in keratinizing carcinoma and high expression was related to short survival [ 69 ].

4.2.2. Prognosis, Treatment Response, and Monitoring

Plasma YKL-40 is elevated, defined as higher than the age-adjusted 95 th percentile of plasma YKL-40 in healthy subjects, in 53% of patients with head and neck cancer [ 69 ] and increased with stage in patients with cervix squamous cell carcinoma [ 66 , 67 ], Figure 4 . High pre-treatment plasma level of YKL-40 is an independent prognostic biomarker of short overall survival in patients with head and neck and cervix squamous cell carcinoma [ 67 , 68 ], Table 1 . It is not known if pre-treatment plasma YKL-40 is a predictor of treatment response in these patients. A longitudinal study of patients with squamous cell carcinoma of the head and neck (TNM stage III and IV) showed that lack of decrease in plasma YKL-40 two months after radiotherapy compared to pretreatment value was accompanied by short survival. Furthermore, an increase in plasma YKL-40 during follow-up in these patients predicted short survival [ 68 ].

4.3. Small Cell Lung Carcinoma

4.3.1. Tissue

YKL-40 mRNA expression is not found in small cell lung cancer cells but was high in the tumor associated macrophages [ 70 ]. Human and mice small cell lung cancer cells do not produce YKL-40 in vitro [ 70 ].

4.3.2. Prognosis, Treatment Response, and Monitoring

Plasma YKL-40 is elevated, defined as higher than the age-adjusted 95 th percentile of plasma YKL-40 in healthy subjects, in a subgroup of patients with localized or advanced small cell lung carcinoma [ 71 ], Figure 4 . High pre-treatment plasma YKL-40 levels before chemotherapy independently predicted short survival [ 71 ], Table 1 .

4.4. Renal Cell Carcinoma

4.4.1. Tissue

YKL-40 protein expression is found in renal cell carcinoma (personal observation, NCBI).

4.4.2. Prognosis, Treatment Response, and Monitoring

Plasma YKL-40 is elevated, defined as higher than the age-adjusted 95 th percentile of plasma YKL-40 in healthy subjects, in approximately 80% of patients with metastatic renal cell carcinoma [ 72 ]. Multivariate analysis including YKL-40, LDH and performance status showed that high plasma YKL-40 was an independent biomarker of short survival [ 72 ], Table 1 .

4.5. Melanoma

4.5.1. Tissue

YKL-40 protein expression is found in melanoma cells and in tumor associated macrophages, Figure 3 G. It has not been evaluated if YKL-40 expression score in melanoma is related to progression free survival or overall survival. Melanoma cells in vitro produce YKL-40 (personal observation).

4.5.2. Prognosis, Treatment Response, and Monitoring

Plasma YKL-40 is elevated, defined as higher than the age-adjusted 95 th percentile of plasma YKL-40 in healthy subjects, in 45% of patients with metastatic melanoma and in 13% of patients with stage I melanoma [ 73 , 74 ], Figure 4 . Pre-treatment plasma YKL-40 is an independent prognostic biomarker in patients with stage I, II, and IV melanoma [ 73 , 74 ]. High plasma YKL-40 in patients after surgery for stage IIB-III melanoma is associated with poor survival in patients not receiving adjuvant interferon therapy [ 75 ], Table 1 . In patients operated for stage I and II melanoma an association was found between high plasma YKL-40 during follow-up and short recurrence-free survival and overall survival [ 74 ]. An increase in plasma YKL-40 compared to the previous measurement was also associated to shorter overall survival in stage IIB-III melanoma patients during follow-up or treatment with adjuvant interferon [ 75 ].

4.6. Glioblastoma

4.6.1. Tissue

In vitro , the U87 glioblastoma cell line [ 76 , 77 ] and the glioma cell lines U1242MG, U343MG and U1231MG [ 78 ] secrete YKL-40 . Microarray gene analyses showed that YKL-40 is overexpressed, compared to normal tissue, in glioblastomas [ 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 ] and astrocytomas [ 78 ]. YKL-40 mRNA and protein expressions increases with glioma grade and are higher in glioblastoma than in astrocytic and oligodendroglial tumors [ 87 , 89 , 90 , 91 , 92 , 93 ]. Furthermore, YKL-40 expression is inversely associated with epidermal growth factor receptor (EGFR) in glioblastoma, with loss of chromosome 10q [ 89 ] and tends to be higher in astrocytomas with 10q23 loss of heterozygosity (LOH) [ 84 , 93 ]. High YKL-40 expression was associated with poor radiation response and short time to disease progression and death [ 77 , 84 , 89 , 90 , 91 ]. Underscoring YKL-40’s association with behaviour, it has been identified as part of a nine-gene paraffin tissue-based expression panel that most closely predicts survival in patients with glioblastoma [ 94 ]. Patients with EGFRvIII-negative/YKL-40-negative tumors had the best prognosis [ 91 ]. High YKL-40 protein expression was also associated with loss of chromosome 10q but not with amplification of EGFR. In pediatric high-grade gliomas YKL-40 overexpression is less frequent than in adult high-grade gliomas and does not correlated with survival [ 95 ].

4.6.2. Prognosis, Treatment Response, and Monitoring

Plasma YKL-40 is elevated, defined as higher than the age-adjusted 95 th percentile of plasma YKL-40 in healthy subjects, in 57–72% of patients with glioblastoma [ 81 , 94 ], Figure 4 . Baseline plasma YKL-40 was an independent prognostic biomarker of decreased survival in patients glioblastoma [ 94 ], Table 1 . In patients operated for high-grade gliomas plasma YKL-40 during follow-up was lower in patients with no radiographic evidence of disease compared to patients with signs of disease, and high plasma YKL-40 during follow-up was associated with short survival [ 94 ]. However, any benefit of initiating treatment on the basis of this information is not known.

4.7. Hematological Malignancies

4.7.1. Tissue

YKL-40 protein expression has not been evaluated in tissue from patients with leukemia and lymphoma. In myeloma, YKL-40 originates from cells in the bone marrow microenvironment surrounding the myeloma cells [ 96 ]. A few myeloma cell lines [ 96 ] and some tumor cell lines originating from immature cells of the monocytic differentiation lineage produce YKL-40 in vitro [ 4 , 97 , 98 ].

4.7.2. Prognosis, Treatment Response, and Monitoring

Plasma YKL-40 is elevated in some patients with acute myeloid leukemia [ 99 ], multiple myeloma [ 96 , 100 , 101 ], and Hodgkin lymphoma [ 102 ], and high pre-treatment plasma YKL-40 is associated with short survival [ 96 , 99 , 100 ]. Patients with myeloma and high plasma YKL-40 had more severe bone destruction including increased bone resorptive activity and early progression of myeloma-related bone disease [ 100 ]. In patients with Hodgkin lymphoma and myeloma high correlations were found between plasma YKL-40 and interleukin (IL)-6 [ 101 , 102 ].

4.8. Cancer Stem Cells

4.8.1. Tissue

YKL-40 protein expression is found in tissue from embryonal carcinoma, Figure 1 D. There are no publications evaluating YKL-40 production by cancer stem cells.

5. Plasma YKL-40 in Patients with Non-Malignant Diseases Characterized by Inflammation, Tissue Remodeling and Fibrosis

High plasma YKL-40 levels are also found in patients with non-malignant diseases characterized by inflammation, increased extracellular tissue remodeling and ongoing fibrosis. It is therefore very important to take into account any co-morbiditiy in patients with cancer, since a high plasma YKL-40 level may also originate from non-malignant cells.

5.1. Inflammatory Diseases

YKL-40 is an acute phase protein because its plasma concentration increases more than 25% following an inflammatory stimulus. Plasma YKL-40 is suggested to be a biomarker of acute and chronic inflammation [ 25 , 103 ], including systemic low-grade inflammation [ 104 ]. In contrast to serum CRP, that is produced in the liver by hepatocytes in response to high IL-6 levels [ 105 , 106 ], YKL-40 is produced locally in tissues with inflammation by macrophages and neutrophils. No or low correlations are found between plasma YKL-40 and CRP, suggesting that these biomarkers reflect different aspects of the inflammatory process, and that plasma YKL-40 provides independent information of inflammation.

Plasma YKL-40 correlated with plasma IL-6 levels in 80-year old women and men, and with serum tumor necrosis factor (TNF)α and CRP in 80-year old women. High plasma YKL-40 was also associated with a low CD4:CD8 cell ratio, and with all-cause mortality, independent of sex, smoking, BMI, chronic disease and anti-inflammatory medicine [ 104 ]. In 482 subjects without cardiovascular disease or type 2 diabetes plasma YKL-40 independently predicted cardiovascular mortality and all cause mortality [ 107 ].

5.1.1. Infectious Diseases

YKL-40 is located in the specific granules of neutrophils [ 108 ] and macrophages produce YKL-40 [ 3 , 4 , 19 ]. Patients with Streptococcus pneumoniae pneumonia, bacteremia and sepsis have ~10-fold higher plasma YKL-40 compared to healthy subjects [ 109 , 110 , 111 ]. Human endotoxaemia, characterized by increased plasma TNFα and IL-6 levels, increases plasma YKL-40 [ 112 ]. Plasma and cerebrospinal fluid concentration of YKL-40 is associated to severity and prognosis of patients with bacterial infection, and plasma YKL-40 may add independent information of prognosis [ 109 , 110 , 111 , 113 ]. Plasma YKL-40 decreases faster to normal levels than CRP in patients who recover from an disease [ 109 ].

5.1.2. Cardiovascular Diseases

In vivo , YKL-40 is expressed by macrophages in atherosclerotic plaques [ 114 ]. In vitro YKL-40 is produced by macrophages during late state of differentiation [ 3 , 4 , 19 ], by differentiated vascular smooth muscle cells [ 115 , 116 , 117 , 118 ] and by endothelial cells [ 119 ]. Recent studies suggest that plasma YKL-40 may be a potential biomarker in patients with cardiovascular disease [ 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 ]. Plasma YKL-40 increases in patients after an acute myocardial infarction [ 120 , 121 ] and is associated with the number of diseased vessels assessed by coronary angiography [ 122 , 123 ]. Plasma YKL-40 correlated with creatine kinase fraction B in non-thrombolyzed patients with acute myocardial infarction [ 120 ]. Elevated plasma YKL-40 is found in some patients with atrial fibrillation [ 124 , 125 ]. A study of 4298 patients with stable coronary artery disease showed that high plasma YKL-40 independently predicted cardiovascular mortality and all cause mortality [ 126 ]. It is not known if plasma YKL-40 reflects the total burden of coronary atherosclerosis or identifies a high-risk atherosclerosis phenotype with ongoing inflammation and severe atherosclerotic plaques. In a smaller study of patients with chronic heart failure plasma YKL-40 was elevated compared to healthy age-matched subjects, but was not associated with New York Heart Association (NYHA) classification, other clinical characteristics or prognosis [ 127 ].

5.1.3. Diabetes

Patients with type 2 diabetes have higher plasma YKL-40 levels compared to subjects with normal glucose tolerance [ 9 , 129 , 130 ], and plasma YKL-40 is related to insulin resistance [ 129 ], fasting plasma glucose, and plasma IL-6 [ 130 ], but not to serum CRP [ 129 ] or obesity [ 130 ]. Patients with type 1 diabetes have elevated plasma YKL-40 compared to healthy subjects, and increasing plasma YKL-40 levels are associated with increasing levels of albuminuria [ 131 ]. It is suggested that plasma YKL-40 is an emerging biomarker in patients with cardiovascular disease and diabetes [ 132 ].

5.1.4. Rheumatic Diseases

YKL-40 is produced by arthritic chondrocytes [ 7 , 133 , 134 ], synoviocytes and fibroblast-like synovial cells [ 7 , 135 , 136 ], and by macrophages in inflamed synovial tissue [ 133 , 137 ]. In patients with rheumatoid arthritis YKL-40 protein is expressed by CD16+ monocytes with a dim expression of CD14 [ 137 ]. This phenotype can differentiate from classic CD14++ monocytes by maturation in vitro and is considered as pro-inflammatory with properties of tissue macrophages and are a source of TNFα [ 138 ]. Patients with very active rheumatoid arthritis have elevated plasma YKL-40 [ 9 , 31 , 133 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 ] compared to healthy subjects and patients with inactive rheumatoid arthritis. Plasma YKL-40 is related to clinical parameters of disease activity and serum CRP, and in a few studies also with progression of joint destruction [ 139 , 140 ]. However, plasma YKL-40 did not provide better clinical information of disease activity and prognosis in patients with rheumatoid arthritis compared to serum CRP.

Few patients with osteoarthritis have elevated plasma YKL-40 [ 133 , 148 ], and only if they have severe synovitis of large joints like a knee joint [ 133 ].

YKL-40 is expressed by macrophages and giant cells in arteritic vessels [ 119 ]. Patients with giant cell arteritis have elevated plasma YKL-40 at time of diagnosis, but during treatment with glucocorticoids plasma YKL-40 was not related to disease activity and serum CRP [ 119 ].

5.1.5. Lung Diseases

YKL-40 is expressed by macrophages in bronchial-biopsy specimens and cytospin of broncho-alveolar lavage from patients with asthma [ 149 ] and chronic obstructive pulmonary disease (COPD) [ 150 ], and in sarcoid lesions of patients with pulmonary sarcoidosis [ 151 ]. YKL-40 is also produced by mast cells [ 24 , 43 ]. YKL-40 concentrations in plasma and bronchoalveolar lavage are higher in smokers with COPD than smokers without COPD [ 150 ] and associated with airflow obstruction and impaired diffusion lung capacity. Plasma YKL-40 levels are elevated in some patients with asthma compared to healthy subjects, and is associated with the severity of asthma measured by clinical variables, including FEV1, and with thickness of the subepithelial basement membrane in biopsy specimens of the lung [ 149 ]. YKL-40 levels in plasma and bronchoalveolar-lavage-fluid increase 24 hours after allergen challenge in patients with allergic asthma, and correlate with eosinophil counts 24 hours after allergen challenge [ 149 , 152 ]. Plasma YKL-40 is higher in patients with pulmonary sarcoidosis compared to healthy subjects and correlated with serum angiotensin-converting enzyme [ 151 ]. Patients with systemic sclerosis and elevated plasma YKL-40 have poor prognosis and often die due to extensive interstitial or vascular fibrosing processes [ 153 , 154 ]. It has therefore been suggested that plasma YKL-40 is a potential new biomarker in patients with inflammatory lung diseases [ 103 , 155 ].

5.1.6. Inflammatory Bowel Diseases

Elevated plasma YKL-40 levels are found in patients with active inflammatory bowel disease [ 142 , 156 , 157 , 158 , 159 ]. In patients with ulcerative colitis plasma YKL-40 correlated with serum CRP and a disease activity score [ 156 , 158 ]. In patients with Crohn’s disease both low relations between plasma YKL-40 and disease activity score [ 158 ], and high relations between plasma YKL-40 and activity score [ 156 ] are reported. Patients with inflammatory bowel disease and joint involvement have higher plasma YKL-40 than patients without joint involvement [ 157 ]. Patients with Crohn’s disease and stenotic disease have higher plasma YKL-40 than patients with non-stenotic disease and plasma YKL-40 was independent of other clinical parameters [ 156 , 159 ]. Thus, plasma YKL-40 may reflect ongoing fibrogenesis and may be a risk factor in patients with Crohn’s disease.

5.2. Liver Fibrosis

High YKL-40 protein expression is found in fibrotic liver tissue from patients with alcoholic liver disease and chronic hepatitis C virus infection [ 160 , 161 ]. Hepatocytes do not express YKL-40 protein and no expression is found in normal liver tissue except in mesenchymal structures of the portal tract. It is most likely that hepatic stellate cells, leucocytes and macrophages produce YKL-40 in the fibrotic liver [ 160 , 161 ]. In biopsies with chronic active hepatitis C virus YKL-40 protein expression was found in areas with piecemeal necrosis, but not in lymphocytes.

In 8899 subjects from the general population increasing plasma levels of YKL-40 were found with increasing alcohol intake [ 27 ]. Plasma YKL-40 is elevated in most patients with moderate to severe liver fibrosis and cirrhosis, independently of disease etiology, and may provide new information of ongoing fibrogenesis in the liver [ 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 ]. In patients with alcoholic liver disease elevated plasma YKL-40 is related to liver fibrosis and inflammation in the liver [ 160 , 161 , 164 ], and patients with very high plasma YKL-40 have shorter survival than patients with normal plasma YKL-40 [ 163 ]. Plasma YKL-40 predict cirrhosis (Ishak 5/6) in patients with chronic hepatitis C, but was not included in the final three-variable model consisting of serum hyaluronan, tissue inhibitor of metalloprotinases (TIMP)-1 and platelet count [ 171 , 172 ]. In children, plasma YKL-40 could not differentiate patients with advanced liver fibrosis from those with mild fibrosis [ 173 ].

6. What Is the Function of YKL-40?

The biological functions of YKL-40 in cancer are unknown. YKL-40 may play different roles depending upon the cell types and environment. YKL-40 probably has a role in proliferation and differentiation of malignant cells and protects the cells from apoptosis. YKL-40 also stimulates angiogenesis and has an effect on extracellular tissue remodeling, and YKL-40 regulates fibroblast activity and increases the degree of fibrosis surrounding cancer cells, although in vivo proofs are yet to be obtained [ 25 , 34 , 35 ]. Membrane receptors of YKL-40 are not described. YKL-40 induced activation of intracellular signal-transduction pathways suggests that it interacts with signaling components on the cell membrane [ 179 , 180 , 181 ]. A thorough understanding of the pathobiology of a putative novel biomarker is not essential regarding its diagnostic or prognostic performance as a biomarker. However, pathophysiological information is very useful in providing support for the validity of the clinical observations, as well as direct research that pertains to possible diagnostic and therapeutic applications.

6.1. Single Nucleotide Polymorphism (SNP)

Studies are ongoing to describe genetic variants of YKL-40 in the general population. The level of YKL-40 expression may in some cases be genetically regulated. The most tested SNP-131 C/G in the promoter region of the YKL-40 gene did not differ between patients with glioblastoma and controls, and no correlation was found between this genotype and YKL-40 expression in glioblastoma samples [ 182 ]. There was no difference in survival between the CC, CG, and GG glioblastoma patients despite the few GG patients tended to have a longer survival [ 182 ]. In other diseases SNP-131 C/G is associated with: (1) elevated plasma YKL-40 levels in patients with asthma, bronchial hyper responsiveness and pulmonary function in the Hutterites [ 183 ]; and (2) plasma YKL-40 levels and the severity of hepatitis C virus induced liver fibrosis [ 162 ]. An association is found between schizophrenia and haplotypes within the promoter region of the YKL-40 gene including SNP-131 C/G [ 184 , 185 , 186 ]. A meta-analysis suggests that the genetic variants in the YKL-40 gene have ethnic heterogeneity and confer a susceptibility to schizophrenia in Asian populations [ 186 ]. In patients with rheumatoid arthritis no association was found to SNP-131 C/G [ 187 ]. SNP-329 G/A in the YKL-40 gene are related to plasma YKL-40 levels in healthy subjects but not in patients with sarcoidosis [ 188 ]. In Danish patients with type 2 diabetes [ 189 ] and asthma and atopy [ 190 ] none of the reported SNPs or haplotype blocks of the YKL-40 gene were associated with these diseases.

6.2. Growth Factor

Studies of embryonic and fetal cells [ 5 ], macrophages [ 3 , 4 , 19 , 191 , 192 , 193 ] and fetal chondrocytes [ 5 , 194 , 195 , 196 ] suggest that YKL-40 is a proliferation and differentiation marker. YKL-40 is strongly expressed in the three germ layers of human embryos and exists in two different isoforms in early human fetal tissue derivatives of ecto-, meso- and endoderm. At the cellular level YKL-40 protein expression was high in embryonic and fetal tissues characterized by rapid proliferation and marked differentiation, and in tissues undergoing morphogenetic changes [ 5 ]. We have also observed that YKL-40 is produced by undifferentiated human embryonic stem cells and their progenitors in differentiating human embryonic stem cells colonies [ 23 ]. Embryonal carcinoma also expresses YKL-40 protein and studies are ongoing to test if YKL-40 is produced by different types of cancer stem cells.

6.3. Protection Factor

YKL-40 expression increases in human glioblastoma cells following stress stimuli such as hypoxia, serum depletion, ionizing radiation and chemotherapy [ 76 ]. The response is late, 24 hours to 72 hours after stimuli, indicating that YKL-40 is a secondary response downstream of other mechanisms. Astrocytes transfected with YKL-40 have increased resistance to serum depletion and radiation as well as increased invasion potential [ 84 ]. Tumor growth of the human U87 glioblastoma cells as xenografts on nude mice is delayed by treatment with monoclonal antibodies against human YKL-40 [ 197 ], suggesting that YKL-40 may be a potential cancer target. In vivo , in glioblastoma cells, a positive association between YKL-40 and activated AKT1 pathways and MAPK intermediates was found [ 91 ]. It was hypothesized that YKL-40 as a secreted protein may serve as an extracellular signal, inducing increased downstream activity of Ras [ 198 ], or may be a surrogate measurement of Ras/PI3-K activation [ 91 ].

YKL-40 initiates PI-3K signalling pathways and phosphorylation of AKT [ 179 , 180 , 181 ] and may be an anti-apoptotic protein [ 199 ]. YKL-40 is also called "breast regression protein (Brp-39)" [ 15 ], since it is induced in mice mammary epithelial cells a few days after weaning. Mammary involution involves programmed cell death. It is suggested that YKL-40 utilizes a chitin oligosaccharide binding ability while participating in the various signal transduction pathways that leads to apoptosis of the regressing cells and that YKL-40 is a protective signalling factor determining which cells are to survive the high tissue remode that occurs during involution [ 13 ].

6.4. Angiogenesis

A recent study has identified YKL-40 as a promoter of angiogenesis in cancer, including activating the MAPK/ERK pathway in endothelial cell [ 200 ]. Transfection of the human glioblastoma cell line U87 with short-interfering RNA against vascular endothelial growth factor (VEGF-A) and implantation on a chick chorio-allantoic membrane resulted in an up-regulation of YKL-40 [ 77 ]. This suggests a role of YKL-40 in regulating response of cancer cells to hypoxia. YKL-40 is also synthesized by vascular smooth muscle cells [ 8 , 115 , 116 , 117 , 118 ], stimulates migration of endothelial cells [ 117 ], and promotes vascular smooth muscle cell attachment, spreading and migration [ 118 ] suggesting a function in angiogenesis and thereby playing a role in the growth of the tumor [ 201 ].

6.5. Inflammation

YKL-40 plays a pathogenetic role in colitis by enhancing the adhesion and invasion of bacteria on/into colonic epithelial cells, and leads to exacerbations of intestinal inflammation [ 202 , 203 , 204 ]. YKL-40 is an autoantigen in rheumatoid arthritis and may have a fundamental role in the pathophysiology of rheumatoid arthritis [ 137 , 205 , 206 , 207 , 208 , 209 , 210 , 211 ]. Studies of patients with asthma suggest that YKL-40 has a role in the innate immune response [ 149 , 212 ]. A study of Brp-39 (the mouse homologue of YKL-40) in Brp-39 −/− mice, YKL-40 transgenic mice, and mice that lack Brp-39 and produce YKL-40 only in their pulmonary epithelium found that Brp-39/YKL-40 has several important functions: (1) it is an inhibitor of macrophage, T-cell, and eosinophil death receptor-mediated apoptosis/cell death and is associated with augmented protein kinase B (PKB)/AKT phosphorylation and Faim 3 induction; (2) it plays a role in the pathogenesis of the IL-13 effector responses that generate inflammation and air-way remodelling; (3) it stimulates accumulation and activation of pulmonary dendritic cells and macrophages; and (4) it is involved in antigen-induced sensitization and IgE induction [ 199 ].

6.6. Tissue Remodeling and Development of Fibrosis

The stroma around the periphery of solid tumors has many similarities with granulation tissue such as that found in wound-healing or inflammation, and regulates essential aspects of tumor proliferation, cell death, progression, matrix remodeling and angiogenesis, and subsequently promotes tumor growth and progression of metastatic disease [ 213 , 214 , 215 , 216 , 217 , 218 , 219 , 220 , 221 , 222 ]. YKL-40 is a proliferation factor of fibroblasts [ 14 , 179 ] and acts synergistically with IGF-1 [ 179 ]. YKL-40 secreted by cancer cells and inflammatory cells surrounding and infiltrating the tumor may play a role in proliferation, activation and differentiation of the fibroblasts/myofibroblasts surrounding the tumor. YKL-40 could thereby influence development of the prominent desmoplastic stroma seen in both primary cancer and metastatic sites. This phenomenon, termed stromal reaction, includes activation of fibroblasts and myofibroblasts transformation, inflammation, secretion of cytokines, matrix proteins and metalloproteinases, and angiogenesis. All play a role in cancer development and metastatic potential, affecting the proliferation, differentiation, invasion or regression of cancer cells, particularly in cancers of epithelial origin [ 221 , 223 , 224 , 225 , 226 ].

YKL-40 is regulated in chondrocytes by TNFα [ 180 , 181 ] and requires sustained activation of NF-κB [ 181 ], which controls cell survival by regulating cell proliferation, growth arrest and death [ 214 ]. YKL-40 initiates MAP kinase and PI-3K signalling cascades in fibroblasts leading to phosphorylation of the extracellular signal-regulated kinase (ERK)-1/2 MAP kinase and PKB/AKT-mediated signalling cascades, which are associated with the control of mitogenesis [ 179 , 180 , 181 ]. Stimulation of articular chondrocytes or skin fibroblasts with IL-1 or TNFα in the presence of YKL-40 results in reduction of both p38 and SAPK/JNK phosphorylation, and YKL-40 suppresses the cytokine-induced secretion of several metalloproteinase and the chemokine IL-8 [ 181 ]. This suggests that YKL-40 may play a protective role in inflammatory environments, limiting degradation of the extracellular matrix and thereby controlling tissue remodelling.

YKL-40 binds collagen type I, II and III and modulates the rate of type I collagen fibril formation [ 227 ]. YKL-40 also binds chitin, but has no chitinase activity [ 7 , 19 , 21 ] due to amino acid substitution in the active site of chitinases [ 7 , 19 ]. YKL-40 contributes to chondrocyte differentiation by inducing the transcription factor SOX9 and type II collagen expressions, and the induction of SOX9 depends on ERK1/2 and PI3K activities, but not on p38 and JNK MAPK [ 228 ]. Vertebrates in an embryonic stage use short chito-oligosaccharides as primers for the synthesis of hyaluronan [ 229 , 230 , 231 ]. YKL-40 has heparin and hyaluronan binding motifs [ 20 ] and may bind to cell surface receptors such as heparin sulphate proteoglycans and may recognize hyaluronan or its precursor as a substrate in the extracellular matrix and interfere with the synthesis and local concentrations of hyaluronan [ 20 ]. YKL-40 may influence the effects of high hyaluronan in tissues, e.g., the extent of cell adhesion and migration during the tissue remodelling processes that take place during metastasis, inflammation, fibrosis, and atherogenesis [ 232 , 233 ]. Furthermore, YKL-40 secreted from macrophages in adipose tissue inhibits degradation of type I collagen and increases the rate of fibril formation of type I collagen [ 234 ].

7. Plasma YKL-40—A New Cancer Biomarker?

The first paper regarding plasma YKL-40 levels in cancer patients was published in 1995 [ 32 ]. Unfortunately, it is still unknown whether determination of plasma levels of YKL-40 can be useful in clinical practice. The pivotal criterion with regard to the potential clinical value of a candidate cancer biomarker is the consistency and strenght of the association between the biomarker and the outcome or disease of interest, and the extent to which it is an improvement on either adding to or replacing established tools. The clinical utility of the biomarker should also be demonstrated by showing that result-based decisions improve patient outcome [ 235 , 236 , 237 , 238 ].

It needs to be determined if routine measurement of plasma YKL-40 in patients with cancer can provide useful clinical information for risk assessment, for treatment selection or for monitoring patients after intervention with different therapeutics. At present plasma YKL-40 can not be regarded as a new cancer biomarker, and FDA has not yet approved the use of plasma YKL-40 as a biomarker in patients with cancer or any other disease. Assessment of the clinical potential of a novel biomarker can be structured around three fundamental questions [ 239 ]: Can the clinician measure the biomarker and is the method specific, sensitive, fast and cheap? Does the biomarker level add new information of the disease? Does the biomarker level help the clinician to treat patients?

Plasma levels of YKL-40 can be measured accurately and fast with relatively low cost, but it is not known if plasma YKL-40 in an individual cancer patient is so reliable that it can be used to make clinical decisions that will improve outcome of the patient.

In order to propose guidelines on how promising tumor markers progress from the laboratory into the clinic, Hayes introduced the “Tumor Marker Utility Grading System” [ 236 , 237 ]. According to this system a number of validation requirements have to be fulfilled before plasma YKL-40 can be considered to be a cancer biomarker. Most of the plasma YKL-40 biomarker studies are retrospective and the blood samples were not collected with the intent of testing the value of plasma YKL-40 as a diagnostic, prognostic, predictive and monitoring biomarker. There are therefore many limitations to the conclusions made from the present studies of plasma YKL-40 as a biomarker. According to the “Tumor Marker Utility Grading System” guidelines [ 236 , 237 ], the next step would be to launch an appropriate prospective study where the benefit of using plasma YKL-40 levels in the clinical decision-making process is assessed. Endpoints should include overall survival, disease-free survival, quality of life and cost-effectiveness. The study could be designed either as a single, highly-powered, prospective, controlled study with the primary objective of testing plasma YKL-40 level as a “prognosticator” or a similar prospective study where the primary goal could be the testing of a therapeutic hypothesis and secondly testing plasma YKL-40 as a biomarker. Such studies will hopefully be designed. Recently, it has been reported that YKL-40 in combination with a panel of biomarkers can give important information in preclinical drug development [ 240 ].

The term “cancer biomarker” embraces a spectrum of molecules of widely divergent characteristics, but sharing an association with malignancy that facilitates their application in the clinical detection (screening, diagnosis) and management (prognosis, monitoring) of cancer patients [ 238 ]. Table 2 summarizes what is presently known about plasma YKL-40 as a potential new cancer biomarker. YKL-40 is neither organ nor tumor specific. Plasma YKL-40 levels may have a role in screening for gastrointestinal cancer or identifying patients at risk [ 27 , 47 ]. Elevated plasma YKL-40 levels, compared to age-matched healthy subjects, are found in patients with 16 different types of cancer. Eighteen studies of 13 different types of cancer have shown that high pretreatment plasma YKL-40 is related to poor prognosis. Highest plasma YKL-40 levels are found in patients with metastatic cancer and plasma YKL-40 provides independent information of recurrence- and progression free survival and of overall survival. The potential values of plasma YKL-40 as a biomarker in monitoring and screening of cancer need more studies, and its value in combinations with other biomarkers has to be determined. It is likely that plasma YKL-40 should be combined in panels of biomarkers for optimal clinical use, since most biomarkers will probably individually lack optimal sensitivity and specificity. A study of patients with pancreatic cancer suggests that this may be useful [ 29 ].

However, YKL-40 is not cancer specific, and high plasma YKL-40 levels are also found in patients with diseases characterized by inflammation, tissue remodelling and fibrosis. Co-morbidity should therefore always be considered in cancer patients.

8. Future

Much more basic research related to the function and regulation of YKL-40 is needed and many fundamental questions regarding YKL-40 remain to be answered. The biological functions of YKL-40 are unclear and its role in cancer development and the mechanisms by which it reflects cancer aggressiveness and cancer progression are poorly understood. The mechanisms by which stimuli lead to increased expression and synthesis of YKL-40 are unknown. It is likely that YKL-40 has a receptor, but it has not yet been identified. YKL-40 is produced by embryonic stem cells and embryonal carcinoma, and it probably has important roles in both embryonic and fetal growth and in pathological growth like cancer. It deserves to be tested if cancer stem cells produce YKL-40, and if the protein is related to metastatic potential in combination with a function in inflammation, angiogenesis, apoptosis and tissue remodeling processes and in pathological conditions leading to fibrosis.

Future focused translational research projects combining basic and clinical research are needed in a joint effort to answer the questions: Is plasma YKL-40 a useful clinical biomarker in patients with cancer? Is YKL-40 a target for development of new cancer therapeutics? and with close collaborations between multidisciplinary teams including surgeons, oncologists, pathologists, biochemists, tumor biologists, molecular biologists, biotech companies and the pharmaceutical industry. Without such collaboration it is unlikely that these two questions will ever be answered.

Acknowledgements

The authors thank Kjeld Møllgård, University of Copenhagen for preparing Figure 1 .

References

1. Siena S. Sartore-Bianchi A.S. Di Nicolantonio F. Balfour J. Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer J. Natl. Cancer Inst. 2009 101 1308 1324 10.1093/jnci/djp280 19738166 PMC2758310

2. Atkinson A.J. Jr. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework Clin. Pharmacol. Ther. 2001 69 89 95 10.1067/mcp.2001.113989 11240971

3. Rehli M. Krause S.W. Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation Genomics 1997 43 221 225 10.1006/geno.1997.4778 9244440

4. Rehli M. Niller H.H. Ammon C. Langmann S. Schwarzfischer L. Andreesen R. Krause S.W. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation J. Biol. Chem. 2003 278 44058 44067 12933821 10.1074/jbc.M306792200

5. Johansen J.S. Høyer P.E. Larsen L.A. Price P.A. Møllgård K. YKL-40 protein expression in the early developing human musculoskeletal system J. Histochem. Cytochem. 2007 55 1213 1228 10.1369/jhc.7A7245.2007 17712177

6. Johansen J.S. Williamson M.K. Rice J.S. Price P.A. Identification of proteins secreted by human osteoblastic cells in culture J. Bone Miner. Res. 1992 7 501 512 1615759 10.1002/jbmr.5650070506

7. Hakala B.E. White C. Recklies A.D. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family J. Biol. Chem. 1993 268 25803 25810 8245017

8. Shackelton L.M. Mann D.M. Millis A.J.T. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling J. Biol. Chem. 1995 270 13076 13083 10.1074/jbc.270.22.13076 7768902

9. Harvey S. Weisman M. O'Dell J. Scott T. Krusemeier M. Visor J. Swindlehurst C. Chondrex: new marker of joint disease Clin. Chem. 1998 44 509 516 9510855

10. Bussink A.P. Speijer D. Aerts J.M.F.G. Boot R.G. Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases Genetics 2007 177 959 970 10.1534/genetics.107.075846 17720922 PMC2034658

11. Funkhouser J.D. Aronson N.N. Chitinase family GH18: evolutionary insights from the genomic history of a diverse protein family BMC Evol. Biol. 2007 7 96 10.1186/1471-2148-7-96 17594485 PMC1945033

12. Zaheer-ul-Haq Dala P. Aronson N.N. Madura J.D. Family 18 chitolectins: comparison of MGP40 and HUMGP39 Biochem. Biophys. Res. Commun. 2007 359 221 226 10.1016/j.bbrc.2007.05.074 17543889 PMC2020521

13. Mohanty A.K. Singh G. Paramasivam M. Saravanan K. Jabeen T. Sharma S. Yadav S. Kaur P. Kumar P. Srinivasan A. Singh T.P. Crystal structure of a novel regulatory 40 kDa mammary gland protein (MGP-40) secreted during involution J. Biol. Chem. 2003 278 14451 14460 10.1074/jbc.M208967200 12529329

14. De Ceuninck F. Gaufillier S. Bonnaud A. Sabatini M. Lesur C. Pastoureau P. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes Biochem. Biophys. Res. Commun. 2001 285 926 931 10.1006/bbrc.2001.5253 11467840

15. Morrison B.W. Leder P. Neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors Oncogene 1994 9 3417 3426 7970700

16. Kirkpatrick R.B. Matico R.E. McNulty D.E. Strickler J.E. Rosenberg M. An abundantly secreted glycoprotein from Drosophila melanogaster is related to mammalian secretory proteins produced in rheumatoid tissues and by activated macrophages Gene 1995 153 147 154 10.1016/0378-1119(94)00756-I 7875581

17. Kawamura K. Shibata T. Saget O. Peel D. Bryant P.J. A new family of growth factors produced by the fat body and active on Drosophila imaginal disc cells Development 1999 126 211 219 9847235 10.1242/dev.126.2.211

18. Badariotti F. Kypriotou M. Lelong C. Dubos M.P. Renard E. Galera P. Favrel P. The phylogenetically conserved molluscan chitinase-like protein 1 (Cg-Clp1), homologue of human HC-gp39, stimulates proliferation and regulates synthesis of extracellular matrix components of mammalian chondrocytes J. Biol. Chem. 2006 281 29583 29596 16882657 10.1074/jbc.M605687200

19. Renkema G.H. Boot G.R. Au F.L. Donker-Koopman W.E. Strijland A. Muijsers A.O. Hrebicek M. Aerts J.M.F.G. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages Eur. J. Biochem. 1998 251 504 509 9492324 10.1046/j.1432-1327.1998.2510504.x

20. Fusetti F. Pijning T. Kalk K.H. Bos E. Dijkstra B.W. Crystal structure and carbohydrate binding properties of the human cartilage glycoprotein-39 J. Biol. Chem. 2003 278 37753 37760 12851408 10.1074/jbc.M303137200

21. Houston D.R. Recklies A.D. Krupa J.C. van Aalten D.M.F. Structure and ligand-induced conformational change of the 39-kDa glycoprotein from human articular chondrocytes J. Biol. Chem. 2003 278 30206 30212 12775711 10.1074/jbc.M303371200

22. Henrissat B. Davies G. Structural and sequence-based classification of glycoside hydrolases Curr. Opin. Struct. Biol. 1997 7 637 644 10.1016/S0959-440X(97)80072-3 9345621

23. Johansen J.S. Møllgård K. YKL-40: Common and distinct in cancer and autoimmunity, frequent in early development and abundant in human embryonic stem cells International Symposium Honoring Prof. David Naor Ein Kerem, Jerusalem, Israel 2–3 September 2007 Abstract 18

24. Ringsholt M. Høgdall E.V.S. Johansen J.S. Price P.A. Christensen L.H. YKL-40 protein expression in normal human tissues - an immunohistochemical study J. Mol. Histol. 2007 38 33 43 10.1007/s10735-006-9075-0 17242979

25. Johansen J.S. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer Dan. Med. Bull. 2006 53 172 209 17087877

26. Johansen J.S. Lottenburger T. Nielsen H.J. Jensen J.E.B. Svendsen M.N. Kollerup G. Christensen I.B. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects Cancer Epidemiol. Biomarkers Prev. 2008 17 2603 2608 10.1158/1055-9965.EPI-07-2766 18843001

27. Johansen J.S. Bojesen S.E. Mylin A.K. Frikke-Schmidt R. Price P.A. Nordestgaard B.G. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population J. Clin. Oncol. 2009 27 572 578 19075264 10.1200/JCO.2008.18.8367

28. Fredriksson S. Horecka J. Brustugun O.T. Schlingemann J. Koong A.C. Tibshirani R. Davis R.W. Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer Clin. Chem. 2008 54 582 589 10.1373/clinchem.2007.093195 18171715

29. Chang S.T. Zahn J.M. Horecka J. Kunz P.L. Ford J.M. Fisher G.A. Le Q.T. Chang D.T. Ji H. Koong A.C. Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis J. Transl. Med. 2009 7 105 10.1186/1479-5876-7-105 20003342 PMC2796647

30. Høgdall E.V.S. Johansen J.S. Kjaer S.K. Price P.A. Blaakjaer J. Høgdall C.K. Stability of YKL-40 concentration in blood samples Scand. J. Clin. Lab. Invest. 2000 60 247 252 10.1080/00365510050184886 10943594

31. Johansen J.S. Jensen H.S. Price P.A. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid Br. J. Rheumatol. 1993 32 949 955 10.1093/rheumatology/32.11.949 8220933

32. Johansen J.S. Cintin C. Jørgensen M. Kamby C. Price P.A. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer Eur. J. Cancer 1995 31A 1437 1442 7577068 10.1016/0959-8049(95)00196-p

33. Roslind A. Johansen J.S. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation Methods Mol. Biol. 2009 511 159 184 10.1007/978-1-59745-447-6_7 19347297

34. Johansen J.S. Jensen B.V. Roslind A. Nielsen D. Price P.A. Review Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol. Biomarkers Prev. 2006 15 194 202 10.1158/1055-9965.EPI-05-0011 16492905

35. Johansen J.S. Jensen B.V. Roslind A. Price P.A. Review Is YKL-40 a new therapeutic target in cancer? Expert Opin. Ther. Targets 2007 11 219 234 10.1517/14728222.11.2.219 17227236

36. Høgdall E.V.S. Ringsholt M. Høgdall C.K. Christensen I.J. Johansen J.S. Kjaer S.K. Blaakaer J. Ostenfeld-Møller L. Price P.A. Christensen L.H. YKL-40 tissue expression and plasma levels in patients with ovarian cancer BMC Cancer 2009 9 8 10.1186/1471-2407-9-8 19134206 PMC2645422

37. Thöm I. Schmid K. Burkholder I. Johansen J.S. Bokemeyer C. Schumacher U. Laack E. YKL-40 protein expression in pulmonary adenocarcinoma is not relation to prognosis ASCO Ann. Meet. Proc. 2010 28 Abstract e18129

38. Bi J. Lau S.H. Lv Z.L. Xie D. Li W. Lai Y.R. Zhong J.M. Wu H.Q. Su Q. He Y.L. Zhan W.H. Wen J.M. Guan X.Y. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer Hum. Pathol. 2009 40 1790 1797 10.1016/j.humpath.2009.07.005 19765801

39. Huang Y. Prasad M. Lemon W.J. Hampel H. Wright F.A. Kornacker K. LiVolsi V. Frankel W. Kloos R.T. Eng C. Pellegata N.S. de la Chapelle A. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles Proc. Natl. Acad. Sci. USA 2001 98 15044 15049 10.1073/pnas.251547398 11752453 PMC64980

40. Kim S.H. Das K. Noreen S. Coffman F. Hameed M. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer World J. Surg. Oncol. 2007 5 17 10.1186/1477-7819-5-17 17286869 PMC1802867

41. Qin W. Zhu W. Schlatter L. Miick R. Loy T.S. Atasoy U. Hewett J.E. Sauter E.R. Increased expression of the inflammatory protein YKL-40 in precancers of the breast Int. J. Cancer 2007 121 1536 1542 10.1002/ijc.22881 17565739

42. Roslind A. Johansen J.S. Junker N. Nielsen D.L. Dzaferi H. Price P.A. Balslev E. YKL-40 expression in benign and malignant lesions of the breast: A methodologic study Appl. Immunohistochem. Mol. Morphol. 2007 15 371 381 18091378 10.1097/01.pai.0000213146.77772.6a

43. Roslind A. Knoop A.S. Jensen M.B. Johansen J.S. Nielsen D.L. Price P.A. Balslev E. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer Breast Cancer Res. Treat. 2008 112 275 285 10.1007/s10549-007-9870-7 18157633

44. Lau S.H. Sham J.S.T. Xie D. Tzang C-H. Tang D. Ma N. Hu L. Wang Y. Wen J.-M. Xiao G. Zhang W.-M. Lau G.K.K. Yang M. Guan X.-Y. Clusterin plays an important role in hepatocellular carcinoma metastasis Oncogene 2006 25 1242 1250 10.1038/sj.onc.1209141 16247463

45. Schunkert H. Samani N.J. Elevated C-reactive protein in atherosclerosis – chicken or egg? Editorial N. Engl. J. Med. 2008 359 1953 1955 10.1056/NEJMe0807235 18971498

46. Nielsen H.J. Brünner N. Frederiksen C. Lomholt A.F. King D. Jørgensen L.N. Olsen J. Rahr H.B. Thygesen K. Hoyer U. Laurberg S. Christensen I.J. Danish-Australian Endoscopy Study Group on Colorectal Cancer Detection; Danish Colorectal Cancer Cooperative Group. Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): a novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection Scand. J. Gastroenterol. 2008 43 242 248 10.1080/00365520701523439 18224568

47. Johansen J.S. Christensen I.J. Price P.A. Nielsen H.J. The Danish Colorectal Cancer Study Group . Serum YKL-40 in risk assessment for colorectal cancer. A population based, prospective study of 4987 subjects at risk of colorectal cancer ASCO Ann. Meet. Proc. 2008 26 212 Abstract 4136

48. Jensen B.V. Johansen J.S. Price P.A. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer Clin. Cancer Res. 2003 9 501 512 14555515

49. Johansen J.S. Christensen I.J. Riisbro R. Greenall M. Han C. Price P.A. Smith K. Brünner N. Harris A.L. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival Breast Cancer Res. Treat. 2003 80 15 21 10.1023/A:1024431000710 12889595

50. Coskun U. Yamac D. Gulbahar O. Sancak B. Karaman N. Ozkan S. Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response? Neoplasma 2007 54 348 352 17845129

51. Yamac D. Ozturk B. Coskun U. Tekin E. Sancak B. Yildiz R. Atalay C. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer Adv. Ther. 2008 25 801 809 10.1007/s12325-008-0082-2 18670741

52. Cintin C. Johansen J.S. Christensen I.J. Price P.A. Sørensen S. Nielsen H.J. Serum YKL-40 and colorectal cancer Br. J. Cancer 1999 79 1494 1499 10.1038/sj.bjc.6690238 10188896 PMC2362720

53. Cintin C. Johansen J.S. Christensen I.J. Price P.A. Sørensen S. Nielsen H.J. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival Cancer 2002 95 267 274 10.1002/cncr.10644 12124825

54. Jensen B.V. Spindler K.-L.G. Schou J.V. Christiansen I.J. Høgdall E. Nielsen D. Johannesen H.H. Pfeiffer P. Yilmaz M. Johansen J.S. Association of YKL-40 levels in patient with metastatic colorectal cancer treated with third-line cetuximab and irinotecan with short survival 2010 Gastrointestinal Cancers Symposium Orlando, FL, USA 22–24 January 2010 Abstract 357

55. Diefenbach C.S.M. Shah Z. Iasonos A. Barakat R.R. Levine D.A. Aghajanian C. Sabbatini P. Hensley M.L. Konner J. Tew W. Spriggs D. Fleisher M. Thaler H. Dupont J. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer Gynecol. Oncol. 2007 104 435 442 10.1016/j.ygyno.2006.08.028 17023034

56. Thöm I. Andritzky B. Schuch G. Burkholder I. Edler L. Johansen J.S. Bokemeyer C. Schumacher U. Laack E. Elevated pre-treatment serum concentration of YKL-40 – an independent prognostic biomarker for poor survival in patients with metastatic non-small cell lung cancer Cancer 2010 10.1002/cncr.25196 20564116

57. Schultz N.A. Johnsson A. Johansen J.S. Christensen I.J. Gunnlaugsson A. Byström P. Nygren P. Frödin J.-E. Wøjdemann M. Glimelius B. Berglund Å. Plasma YKL-40 and IL-6, potential new biomarkers for pancreatic cancer and other upper gastrointestinal adenocarcinomas BMC Cancer 2010 submitted

58. Brasso K. Christensen I.J. Johansen J.S. Teisner B. Garnero P. Price P.A. Iversen P. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma Prostate 2006 66 503 513 10.1002/pros.20311 16372331

59. Johansen J.S. Brasso K. Iversen P. Teisner B. Garnero P. Price P.A. Christensen I.J. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival Clin. Cancer Res. 2007 13 3244 3249 10.1158/1078-0432.CCR-06-2616 17545529

60. Kucur M. Isman F.K. Balci C. Onal B. Hacibekiroglu M. Ozkan F. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia Urol. Oncol. 2008 26 47 52 10.1016/j.urolonc.2007.07.020 18190830

61. Høgdall E.V.S. Johansen J.S. Kjaer S.K. Price P.A. Christensen L. Blaakaer J. Bock J.E. Glud E. Høgdall C.K. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival Oncol. Rep. 2003 10 1535 1538 12883737

62. Dehn H. Høgdall E.V.S. Johansen J.S. Price P.A. Jørgensen M. Engelholm S.A.A. Høgdall C.K. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer Acta Obstet. Gynecol. Scand. 2003 82 287 293 10.1034/j.1600-0412.2003.00010.x 12694127

63. Dupont J. Tanwar M.K. Thaler H.T. Fleisher M. Kauff N. Hensley M.L. Sabbatini P. Anderson S. Aghajanian C. Holland E.C. Spriggs D.R. Early detection and prognosis of ovarian cancer using serum YKL-40 J. Clin. Oncol. 2004 22 3330 3339 10.1200/JCO.2004.09.112 15310777

64. Grønlund B. Høgdall E.V.S. Christensen I.J. Johansen J.S. Nørgaard-Pedersen B. Engelholm S.A. Høgdall C. Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA125) Int. J. Biol. Markers 2006 21 141 148 17013795 10.1177/172460080602100302

65. Chudecka-Glaz A. Górski B. Zielinska D. Blogowski W. Wojciechowska I. Bedner R. Rzepka-Górska I. Serum YKL-40 levels in patients with ovarian cancer and women with BRCA1 gene mutation—comparison to CA 125 antigen Eur. J. Gynaecol. Oncol. 2009 30 668 671 20099501

66. Mitsuhashi A. Matsui H. Usui H. Nagai Y. Tate S. Unno Y. Hirashiki K. Seki K. Shozu M. Serum YKL-40 as a marker for cervical adenocarcinoma Ann. Oncol. 2009 20 71 77 18723551 10.1093/annonc/mdn552

67. Johansen J.S. Roslind A. Palle C. Christensen I.J. Nielsen H.J. Price P.A. Nielsen D. Mosgaard B. Serum YKL-40 levels in patients with cervical cancer are elevated compared to patients with cervical intraepithelial neoplasia and healthy controls ASCO Ann. Meet. Proc. 2006 24 267 Abstract 5047

68. Roslind A. Johansen J.S. Christensen I.J. Kiss K. Balslev E. Nielsen D.L. Bentzen J. Price P.A. Andersen E. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival Int. J. Cancer 2008 122 857 863 10.1002/ijc.23152 17957792

69. Castellano I. Mistrangelo M. Crudo V. Chiusa L. Lupo R. Ricardi U. Morino M. Mussa A. Cassoni P. YKL-40 expression in anal carcinoma predicts shorter overall and disease-free survival Histopathology 2009 55 238 240 10.1111/j.1365-2559.2009.03364.x 19694834

70. Junker N. Johansen J.S. Andersen C.B. Kristjansen P.E.G. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer Lung Cancer 2005 48 223 231 10.1016/j.lungcan.2004.11.011 15829322

71. Johansen J.S. Drivsholm L. Price P.A. Christensen I.J. High serum YKL-40 level in patients with small cell lung cancer is related to early death Lung Cancer 2004 46 333 340 10.1016/j.lungcan.2004.05.010 15541818

72. Geertsen P.F. Johansen J.S. von der Maase H. Jensen B.V. Price P.A. High pretreatment serum level of YKL-40 is related to short survival in patients with advanced renal cell carcinoma treated with high-dose continuous intravenous infusion of interleukin-2. ASCO 2004 Ann. Meet. Proc. 2003 22 399 Abstract 1603

73. Schmidt H. Johansen J.S. Gehl J. Geertsen P.F. Fode K. von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma Cancer 2006 106 1130 1139 10.1002/cncr.21678 16456816

74. Schmidt H. Johansen J.S. Sjoegren P. Christensen I.J. Sørensen B.S. Fode K. Larsen J. von der Maase H. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma J. Clin. Oncol. 2006 24 798 804 10.1200/JCO.2005.03.7960 16391295

75. Krogh M. Christensen I.J. Bouwhuis M. Johansen J.S. Schmidt H. Hansson J. Aamdal S. Testori A. Eggermont A.M. Bastholt L. Prognostic value of serum YKL-40 in stage IIB-III melanoma patients receiving adjuvant interferon therapy ASCO Ann. Meet. Proc. 2010 Abstract 8587

76. Junker N. Johansen J.S. Hansen L.T. Lund E.L. Kristjansen P.E.G. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells Cancer Sci. 2005 96 183 190 10.1111/j.1349-7006.2005.00026.x 15771622 PMC11158589

77. Saidi A. Javerzat S. Bellahcene A. De Vos J. Bello L. Castronovo V. Deprez M. Loiseau H. Bikfalvi A. Hagedorn M. Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma Int. J. Cancer 2008 122 2187 2198 18092325 10.1002/ijc.23313

78. Krona A. Aman P. Orndal C. Josefsson A. Oncostatin M-induced genes in human astrocytomas Int. J. Oncol. 2007 31 1457 1463 17982672

79. Lal A. Lash A.E. Altschul S.F. Velculescu V. Zhang L. McLendon R.E. Marra M.A. Prange C. Morin P.J. Polyak K. Papadopoulos N. Vogelstein B. Kinzler K.W. Strausberg R.L. Riggins G.J. A public database for gene expression in human cancers Cancer Res. 1999 59 5403 5407 10554005

80. Markert J.M. Fuller C.M. Gillespie G.Y. Bubien J.K. McLean L.A. Hong R.L. Lee K. Gullans S.R. Mapstone T.B. Benos D.J. Differential gene expression profiling in human brain tumors Physiol. Genomics 2001 5 21 33 11161003 10.1152/physiolgenomics.2001.5.1.21

81. Tanwar M.K. Gilbert M.R. Holland E.C. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma Cancer Res. 2002 62 4364 4368 12154041

82. Shostak K. Labunskyy V. Dmitrenko V. Malisheva T. Shamayev M. Rozumenko V. Zozulya Y. Zehetner G. Kavsan V. HC gp-39 gene is upregulated in glioblastoma Cancer Lett. 2003 198 203 210 10.1016/S0304-3835(03)00310-0 12957359

83. Colin C. Baeza N. Bartoli C. Fina F. Eudes N. Nanni I. Martin P.-M. Ouafik L. Figarella-Branger D. Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization Oncogene 2006 25 2818 2829 10.1038/sj.onc.1209305 16314830

84. Nigro J.M. Misra A. Zhang L. Smirnov I. Colman H. Griffin C. Ozburn N. Chen M. Pan E. Koul D. Yung W.K.A. Feuerstein B.G. Aldape K.D. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma Cancer Res. 2005 65 1678 1686 10.1158/0008-5472.CAN-04-2921 15753362

85. Phillips H.S. Kharbanda S. Chen R. Forrest W.F. Soriano R.H. Wu T.D. Misra A. Nigro J.M. Colman H. Soroceanu L. Williams P.M. Modrusan Z. Feuerstein B.G. Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 2006 9 157 173 10.1016/j.ccr.2006.02.019 16530701

86. Kroes R.A. Dawson G. Moskal J.R. Focused microarray analysis of glyco-gene expression in human glioblastomas J. Neurochem. 2007 103 14 24 10.1111/j.1471-4159.2007.04780.x 17986135

87. Ducray F. Idbaih A. de Reynies A. Bieche I. Thillet J. Mokhtari K. Lair S. Marie Y. Paris S. Vidaud M. Hoang-Xuan K. Delattre O. Delattre J.-Y. Sanson M. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile Mol. Cancer 2008 7 41 10.1186/1476-4598-7-41 18492260 PMC2415112

88. Bhat K.P. Pelloski C.E. Zhang Y. Kim S.H. delaCruz C. Rehli M. Aldape K.B. Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2 FEBS Lett. 2008 582 3193 3200 10.1016/j.febslet.2008.08.010 18708058

89. Pelloski C.E. Mahajan A. Maor M. Chang E.L. Woo S. Gilbert M. Colman H. Yang H. Ledoux A. Blair H. Passe S. Jenkins R.B. Aldape K.D. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma Clin. Cancer Res. 2005 11 3326 3334 10.1158/1078-0432.CCR-04-1765 15867231

90. Nutt C.L. Betensky R.A. Brower M.A. Batchelor T.T. Louis D.N. Stemmer-Rachamimow A.O. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas Clin. Cancer Res. 2005 11 2258 2264 10.1158/1078-0432.CCR-04-1601 15788675

91. Pelloski C.E. Ballman K.V. Furth A.F. Zhang L. Lin E. Sulman E.P. Bhat K. McDonald J.M. Yung W.K.A. Colman H. Woo S.Y. Heimberger A.B. Suki D. Prados M.D. Chang S.M. Barker F.G. II Buckner J.C. James D. Aldape K. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma J. Clin. Oncol. 2007 25 2288 2294 10.1200/JCO.2006.08.0705 17538175

92. Rousseau A. Nutt C.L. Betensky R.A. Iafrate J. Han M. Ligon K.L. Rowitch D.H. Louis D.N. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2 J. Neuropathol. Exp. Neurol. 2006 65 1149 1156 10.1097/01.jnen.0000248543.90304.2b 17146289

93. Horbinski C. Wang G. Wiley C.A. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas Int. J. Clin. Exp. Pathol. 2010 3 226 237 20224722 PMC2836500

94. Hormigo A. Gu B. Karimi S. Riedel E. Panageas K.S. Edgar M.A. Tanwar M.K. Rao J.S. Fleisher M. DeAngelis L.M. Holland E.C. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas Clin. Cancer Res. 2006 12 5698 5704 10.1158/1078-0432.CCR-06-0181 17020973

95. Antonelli M. Buttarelli F.R. Arcella A. Nobusawa S. Donofrio V. Oghaki H. Giangaspero F. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas J. Neurooncol. 2010 10.1007/s11060-010-0129-5 20174854

96. Mylin A.K. Rasmussen T. Johansen J.S. Knudsen L.M. Nørgaard P.H. Lenhoff S. Dahl I.M.S. Johnsen H.E. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells Eur. J. Hematol. 2006 77 416 424 10.1111/j.0902-4441.2006.t01-1-EJH2879.x 16930142

97. Kirkpatrick R.B. Emery J.G. Connor J.R. Dodds R. Lysko P.G. Rosenberg M. Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages Exp. Cell Res. 1997 237 46 54 10.1006/excr.1997.3764 9417865

98. Verhoeckx K.C.M. Bijlsma S. De Groene E.M. Witkamp R.F. van der Greef F. Rodenburg R.J.T. A combination of proteomics, principal component analysis and transcriptomics is a powerful tool for the identification of biomarkes for macrophage maturation in the U937 cell line Proteomics 2004 4 1014 1028 10.1002/pmic.200300669 15048983

99. Bergmann O.J. Johansen J.S. Klausen T.W. Mylin A.K. Kristensen J.S. Kjeldsen E. Johnsen H.E. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia Clin. Cancer Res. 2005 11 8644 8652 10.1158/1078-0432.CCR-05-1317 16361549

100. Mylin A.K. Abildgaard N. Johansen J.S. Andersen N.F. Heickendorff L. Standal T. Gimsing P. Knudsen L.M. High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients Eur. J. Haematol. 2008 80 310 317 10.1111/j.1600-0609.2007.01027.x 18182077

101. Mylin A.K. Andersen N.F. Johansen J.S. Abildgaard N. Heickendorff L. Standal T. Gimsing P. Knudsen L.M. Serum YKL-40 and bone marrow angiogenesis in multiple myeloma Int. J. Cancer 2009 124 1492 1494 10.1002/ijc.24110 19089918

102. Biggar R,J. Johansen J.S. Smedby K.E. Rostgaard K. Chang E.T. Adami H-O. Glimelius B. Molin D. Hamilton-Dutoit S. Melbye M. Hjalgrim H. Serum YKL-40 and IL-6 levels in Hodgkin lymphoma Clin. Cancer Res. 2008 14 6974 6979 10.1158/1078-0432.CCR-08-1026 18980992 PMC2613488

103. Lee C.G. Elias J.A. Role of breast regression protein-39/YKL-40 in asthma and allergic responses Allergy Asthma Immunol. Res. 2010 2 20 27 10.4168/aair.2010.2.1.20 20224674 PMC2831605

104. Johansen J.S. Pedersen A.N. Schroll M. Jørgensen T. Pedersen B.K. Bruunsgaard H. High serum YKL-40 level in a cohort of 80-years old is associated with increased risk of all-cause mortality Clin. Exp. Immunol. 2008 151 260 266 18070151 10.1111/j.1365-2249.2007.03561.x PMC2276948

105. Gabay C. Kushner I. Acute-phase proteins and other systemic responses to inflammation N. Engl. J. Med. 1999 340 448 454 10.1056/NEJM199902113400607 9971870

106. Kushner I. Rzewnicki D. Samols D. What does minor elevation of C-reactive protein signify? Am. J. Med. 2006 166 e17 28 16443421 10.1016/j.amjmed.2005.06.057

107. Rathcke C.N. Raymond I. Kistorp C. Hildebrandt P. Faber J. Vestergaard H. Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population Int. J. Cardiol. 2009 10.1016/j.ijcard.2009.01.043 19223085

108. Volck B. Price P.A. Johansen J.S. Sørensen O. Benfield T. Nielsen H.J. Calafat J. Borregaard N. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils Proc. Assoc. Am. Phys. 1998 110 351 360 9686683

109. Nordenbæk C. Johansen J.S. Junker P. Borregaard N. Sørensen O. Price P.A. YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization J. Infect. Dis. 1999 180 1722 1726 10.1086/315050 10515841

110. Kronborg G. Østergaard C. Weis N. Nielsen H. Obel N. Pedersen S.S. Price P.A. Johansen J.S. Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease Scand. J. Infect. Dis. 2002 34 323 326 10.1080/00365540110080233 12069012

111. Hattori N. Oda S. Sadahiro T. Nakamura M. Abe R. Shinozaki K. Nomura F. Tomonaga T. Matsushita K. Kodera Y. Sogawa K. Satoh M. Hirasawa H. YKL-40 identified by proteomic analysis as a biomarker of sepsis Shock 2009 32 393 400 10.1097/SHK.0b013e31819e2c0c 19197227

112. Johansen J.S. Krabbe K. Møller K. Pedersen B.K. Circulating YKL-40 levels during human endotoxaemia Clin. Exp. Immunol. 2005 140 343 348 10.1111/j.1365-2249.2005.02763.x 15807860 PMC1809363

113. Østergaard C. Johansen J.S. Benfield T. Price P.A. Lundgren J.D. YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis Clin. Diagn. Lab. Immun. 2002 9 598 604 10.1128/CDLI.9.3.598-604.2002 PMC119997 11986266

114. Boot R.G. van Achterberg T.A.E. van Aken B.E. Renkema G.H. Jacobs M.J.H.M. Aerts J.M.F.G. de Vries C.J.M. Strong induction of members of the chitinase family of proteins in atherosclerosis. Chitotriosidase and human cartilage gp-39 expressed in lesion macrophages Arterioscler. Thromb. Vasc. Biol. 1999 19 687 694 10.1161/01.ATV.19.3.687 10073974

115. Millis A.J.T. Hoyle M. Reich E. Mann D.M. Isolation and characterization of a Mr = 38,000 protein from differentiating smooth muscle cells J. Biol. Chem. 1985 260 3754 3761 3972846

116. Millis A.J.T. Hoyle M. Kent L. In vitro expression of a 38,000 dalton heparin-binding glycoprotein by morphologically differentiated smooth muscle cells J. Cell Physiol. 1986 127 366 372 10.1002/jcp.1041270304 3086326

117. Malinda K.M. Ponce L. Kleinman H.K. Shackelton L.M. Millis A.J.T. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells Exp. Cell Res. 1999 250 168 173 10.1006/excr.1999.4511 10388530

118. Nishikawa K.C. Millis A.J.T. Gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells Exp. Cell Res. 2003 287 79 87 10.1016/S0014-4827(03)00069-7 12799184

119. Johansen J.S. Baslund B. Garbarsch C. Hansen M. Stoltenberg M. Lorenzen I. Price P.A. YKL-40 in giant cells and macrophages from patients with giant cell arteritis Arthritis Rheum. 1999 42 2624 2630 10.1002/1529-0131(199912)42:12<2624::AID-ANR17>3.0.CO;2-K 10616010

120. Nøjgaard C. Høst N.B. Christensen I.J. Poulsen S.H. Egstrup K. Price P.A. Johansen J.S. Serum levels of YKL-40 increases in patients with acute myocardial infarction Coron. Artery Dis. 2008 19 257 263 10.1097/MCA.0b013e3282f40dd5 18480670

121. Wang Y. Ripa R.S. Johansen J.S. Gabrielsen A. Steinbrüchel D.A. Friis T. Bindslev L. Haack-Sørensen M. Jørgensen E. Kastrup J. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease Scand. Card. J. 2008 42 295 302 10.1080/14017430802220567 18615353

122. Kucur M. Isman F.K. Karadag B. Vural V.A. Tavsanoglu S. Serum YKL-40 levels in patients with coronary artery disease Coron. Artery Dis. 2007 18 391 396 10.1097/MCA.0b013e328241d991 17627189

123. Zheng J.L. Lu L. Hu J. Zhang R.Y. Zhang Q. Chen Q.J. Shen W.F. Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease Atherosclerosis 2010 210 590 595 20056225 10.1016/j.atherosclerosis.2009.12.016

124. Henningsen K.M. Therkelsen S.K. Johansen J.S. Bruunsgaard H. Svendsen J.H. Plasma YKL-40, a new biomarker for artrial fibrillation? Europace 2009 11 1032 1036 10.1093/europace/eup103 19411674

125. Henningsen K.M. Nilsson B. Johansen J.S. Chen X. Pehrson S. Svendsen J.H. Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation Inflamm. Res. 2010 59 463 469 10.1007/s00011-009-0146-z 20012147

126. Kastrup J. Johansen J.S. Winkel P. Hansen J.F. Hildebrandt P. Jensen G.B. Jespersen C.M. Kjøller E. Kolmos H.J. Lind I.M. Nielsen H. Gluud C. The CLARICOR Trial Group High serum concentration of YKL-40 in patients with stable coronary artery disease is associated with increased risk of myocardial infarction, cardiovascular death and all-cause mortality Eur. Heart J. 2009 30 1066 1072 10.1093/eurheartj/ehp049 19270316

127. Rathcke C.N. Kistorp C. Raymond I. Hildebrandt P. Gustafsson F. Lip G.Y. Faber J. Vestergaard H. Plasma YKL-40 levels are elevated in patients with chronic heart failure Scand. Cardiovasc. J. 2009 Dec 4 Epub ahead of print 10.3109/14017430903402218 19961288

128. Hedegaard A. Ripa R.S. Johansen J.S. Jørgensen E. Kastrup J. Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction Scand. J. Clin. Lab. Invest. 2010 70 80 86 10.3109/00365510903518191 20102300

129. Rathcke C.N. Johansen J.S. Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance Inflamm. Res. 2006 55 53 59 10.1007/s00011-005-0010-8 16612564

130. Nielsen A.R. Erikstrup C. Johansen J.S. Fischer C.P. Plomgaard P. Krogh-Madsen R. Taudorf S. Mortensen O.H. Petersen A.M.W. Lindegaard B. Pedersen B.K. Plasma YKL-40: a BMI-independent marker of type 2 diabetes Diabetes 2008 57 3078 3082 10.2337/db08-0182 18650368 PMC2570404

131. Rathcke C.N. Persson F. Tarnow L. Rossing P. Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria Diabetes Care 2009 32 323 328 18957531 10.2337/dc08-1144 PMC2628702

132. Rathcke C.N. Vestergaard H. YKL-40—an emerging biomarker in cardiovascular disease and diabetes Cardiovasc. Diabetol. 2009 8 61 10.1186/1475-2840-8-61 19930630 PMC2789050

133. Volck B. Johansen J.S. Stoltenberg M. Garbarsch C. Price P.A. Østergaard M. Østergaard K. Løvgreen-Nielsen P. Sonne-Holm S. Lorenzen I. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology Osteoarthr. Cartil. 2001 9 203 214 10.1053/joca.2000.0377 11300743

134. Johansen J.S. Olee T. Price P.A. Hashimoto S. Ochs R.L. Lotz M. Regulation of YKL-40 production by human articular chondrocytes Arthritis Rheum. 2001 44 826 837 10.1002/1529-0131(200104)44:4<826::AID-ANR139>3.0.CO;2-U 11315922

135. Nyirkos P. Golds E.E. Human synovial cells secrete a 39 kDa protein similar to a bovine mammary protein expressed during the non-lactating period Biochem. J. 1990 268 265 268 2375755 10.1042/bj2690265 PMC1131563

136. Dasuri K. Antonovici M. Chen K. Wong K. Standing K. Ens W. El-Gabalawy H. Wilkins J.A. The synovial proteome: analysis of fibroblast-like synoviocytes Arthritis Res. Ther. 2004 6 R161 168 10.1186/ar1153 15059280 PMC400437

137. Baeten D. Boots A.M.H. Steenbakkers P.G.A. Elewaut D. Bos E. Verheijden G.F.M. Verbruggen G. Miltenburg A.M.M. Rijnders A.W.M. Veys E.M. de Keyser F. Human cartilage gp-39+, CD16+ monocytes in peripheral blood and synovium.Correlation with joint destruction in rheumatoid arthritis Arthritis Rheum. 2000 43 1233 1243 10.1002/1529-0131(200006)43:6<1233::AID-ANR6>3.0.CO;2-9 10857782

138. Belge K.U. Dayyani F. Horelt A. Siedlar M. Frankenberger M. Frankenberger B. Espevik T. Ziegler-Heitbrock L. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF J. Immunol. 2002 168 3536 3542 11907116 10.4049/jimmunol.168.7.3536

139. Johansen J.S. Stoltenberg M. Hansen M. Florescu A. Hørslev-Petersen K. Lorenzen I. Price P.A. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity Rheumatology 1999 38 618 626 10.1093/rheumatology/38.7.618 10461474

140. Johansen J.S. Kirwan J.R. Price P.A. Sharif M. Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction Scand. J. Rheumatol. 2001 30 297 304 10.1080/030097401753180381 11727845

141. Harvey S. Whaley J. Eberhardt K. The relationship between serum levels of YKL-40 and disease progression in patients with early rheumatoid arthritis Scand. J. Rheumatol. 2000 29 391 393 10.1080/030097400447606 11132209

142. Vos K. Steenbakkers P. Miltenburg A.M.M. Bos E. van den Heuvel M.V. van Hogezand R.A. de Vries R.R.P. Breedveld F.C. Boots A.M.H. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions Ann. Rheum. Dis. 2000 59 544 548 10.1136/ard.59.7.544 10873965 PMC1753190

143. Combe B. Dougados M. Goupille P. Cantagrel A. Eliaou J.F. Sibilia J. Meyer O. Sany J. Daures J.-P. Dubois A. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study Arthritis Rheum. 2001 44 1736 1743 10.1002/1529-0131(200108)44:8<1736::AID-ART308>3.0.CO;2-I 11508423

144. Peltomaa R. Paimela L. Harvey S. Helve T. Leirisalo-Repo M. Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity Rheumatol. Int. 2001 20 192 196 10.1007/s002960100115 11518039

145. Matsumoto T. Tsurumoto T. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laboratory parameters Clin. Exp. Rheumatol. 2001 19 655 660 11791636

146. Knudsen L.S. Østergaard M. Baslund B. Narvestad E. Petersen J. Nielsen H.J. Ejbjerg B.J. Szkudlarek M. Johansen J.S. Plasma IL-6, plasma VEGF and serum YKL-40: relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate Scand. J. Rheumatol. 2006 35 489 491 10.1080/03009740600904300 17343261

147. Knudsen L.S. Klarlund M. Skjødt H. Jensen T. Østergaard M. Jensen K.E. Hansen M.S. Hetland M.L. Nielsen H.J. Johansen J.S. Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome J. Rheumatol. 2008 35 1277 1287 18597410

148. Sharif M. Granell R. Johansen J.S. Clarke S. Elson C. Kirwan J.R. Serum cartilage oligomeric matrix protein and other biomarker profiles in tibiofemoral and patellofemoral osteoarthritis of the knee Rheumatology 2006 5 522 526 16319098 10.1093/rheumatology/kei216

149. Chupp G.L. Lee C.G. Jarjour N. Shim Y.M. Holm C.T. He S. Dziura J.D. Reed J. Coyle A.J. Kiener P. Cullen M. Grandsaigne M. Dombret M.-C. Aubier M. Pretolani M. Elias J.A. A chitinase–like protein in the lung and circulation of patients with severe asthma N. Engl. J. Med. 2007 357 2016 2027 10.1056/NEJMoa073600 18003958

150. Letuve S. Kozhich A. Arouche N. Grandsaigne M. Reed J. Dombret M.-C. Kiener P.A. Aubier M. Coyle A.J. Pretolani M. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages J. Immunol. 2008 181 5167 5173 18802121 10.4049/jimmunol.181.7.5167

151. Johansen J.S. Milman N. Hansen M. Garbarsch C. Price P.A. Graudal N. Increased serum YKL-40 in patients with pulmonary sarcoidosis. A potential marker of disease activity? Respir. Med 2005 99 396 402 10.1016/j.rmed.2004.09.016 15763444

152. Kuepper M. Bratke K. Virchow J.C. Chitinase-like protein and asthma N. Engl. J. Med. 2008 358 1073 1075 10.1056/NEJMc073406 18322291

153. Montagna G.L. D’Angelo S. Valentini G. Cross-sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease J. Rheumatol. 2003 30 2147 2151 14528508

154. Nordenbæk C.: Johansen J.S. Halberg P. Wiik A. Garbarsch C. Ullman S. Price P.A. Jacobsen S. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement Scand. J. Rheumatol. 2005 34 293 297 10.1080/03009740510018598 16195162

155. Ober C. Chupp G.L. The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseases Curr. Opin. Allergy Clin. Immunol. 2009 9 401 408 10.1097/ACI.0b013e3283306533 19644363 PMC3018778

156. Koutroubakis I.E. Petinaki E. Dimoulios P. Vardas E. Roussomoustakaki M. Maniatis A.N. Kouroumalis E.A. Increased serum levels of YKL-40 in patients with inflammatory bowel disease Int. J. Colorectal Dis. 2003 18 254 259 12673492 10.1007/s00384-002-0446-z

157. Punzi L. Podswiadek M. D’Inca R. Zaninotto M. Bernardi D. Plebani M. Sturniolo G.C. Serum human cartilage glycoprotein 39 as a marker of arthritis associated with inflammatory bowel disease Ann. Rheum. Dis. 2003 62 1224 1226 10.1136/ard.2002.004408 14644865 PMC1754395

158. Vind I. Johansen J.S. Price P.A. Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease Scand. J. Gastroenterol. 2003 38 599 605 10.1080/00365520310000537 12825867

159. Erzin Y. Uzun H. Karatas A. Celik A.F. Serum YKL-40 as a marker of disease activity and stricture formation in patients with Crohn’s disease J. Gastroenterol. Hepatol. 2008 23 e357 362 10.1111/j.1440-1746.2007.05121.x 17725598

160. Johansen J.S. Møller S. Price P.A. Bendtsen F. Junge J. Garbarsch C. Henriksen J.H. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand Scand. J. Gastroenterol. 1997 32 582 590 10.3109/00365529709025104 9200292

161. Johansen J.S. Christoffersen P. Møller S. Price P.A. Henriksen J.H. Garbarsch C. Bendtsen F. Serum YKL-40 is increased in patients with hepatic fibrosis J. Hepatol. 2000 32 911 920 10.1016/S0168-8278(00)80095-1 10898311

162. Berres M.L. Papen S. Pauels K. Schmitz P. Zaldivar M.M. Hellerbrand C. Mueller T. Berg T. Weiskirchen R. Trautwein C. Wasmuth H.E. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection J. Hepatol. 2009 50 370 376 10.1016/j.jhep.2008.09.016 19070929

163. Nøjgaard C. Johansen J.S. Christensen E. Skovgaard L.T. Price P.A. Becker U. The EMALD Group Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease J. Hepatol. 2003 39 179 186 10.1016/S0168-8278(03)00184-3 12873813

164. Tran A. Benzaken S. Saint-Paul M.C. Guzman-Granier E. Hastier P. Pradier C. Barjoan E.M. Demuth N. Longo F. Rampal P. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease Eur. J. Gastroenterol Hepatol. 2000 12 989 993 10.1097/00042737-200012090-00004 11007134

165. Nøjgaard C. Johansen J.S. Krarup H.B. Holten-Andersen M. Møller A. Bendtsen F. Danish Viral Hepatitis Study Group Effect of antiviral therapy on markers of fibrogenesis in patients with chronic hepatitis C Scand. J. Gastroenterol. 2003 38 659 665 10.1080/00365520310002300 12825876

166. Nunes D. Fleming C. Offner G. O’Brien M. Tumilty S. Fix O. Heeren T. Koziel M. Graham C. Craven D.E. Stuver S. Horsburgh C.R. Jr. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease J. Acquir. Immune. Defic. Syndr. 2005 40 538 544 10.1097/01.qai.0000184856.31695.bf 16284529

167. Zheng M. Cai W.M. Zhao J.K. Zhu S.M. Liu R.H. Determination of serum levels of YKL-40 and hyaluronic acid in patients with hepatic fibrosis due to schistosomiasis japonica and appraisal of their clinical value Acta Trop. 2005 96 148 152 10.1016/j.actatropica.2005.07.009 16188216

168. Kamal S.M. Turner B. He Q. Rasenack J. Bianchi L. Tawil A.A. Nooman A. Massoud M. Koziel M.J. Afdhal N.H. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis Hepatology 2006 43 771 779 10.1002/hep.21117 16557547

169. Alexander J. Tung B.Y. Croghan A. Kowdley K.V. Effect of iron depletion on serum markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic hepatitis C: results of a pilot study Liver Int. 2007 27 268 273 10.1111/j.1478-3231.2007.01449.x 17311623

170. Esmat G. Metwally M. Zalata K.R. Gadalla S. Abdel-Hamid M. Abouzied A. Shaheen A.-A. El-Raziky M. Khatab H. El-Kafrawy S. Mikhail N. Magder L.S. Afdhal N.H. Strickland G.T. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C J. Hepatol. 2007 46 620 627 10.1016/j.jhep.2006.12.010 17316875

171. Fontana R.J. Goodman Z.D. Dienstag J.L. Bonkovsky H.L. Naishadham D. Sterling R.K. Su G.L. Ghosh M. Wright E.C. the HALT-C Trial Group Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C Hepatology 2008 47 789 798 10.1002/hep.22099 18175357

172. Fontana R.J. Bonkovsky H.L. Naishadham D. Dienstag J.L. Sterling R.K. Lok A.S. Su G.L. Halt-C Trial Group Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis Clin. Gastroenterol. Hepatol. 2009 7 219 226 10.1016/j.cgh.2008.10.034 19068241 PMC3766729

173. Lebensztejn D.M. Skiba E. Werpachowska I. Sobaniec-Lotowska M.E. Kaczmarksi M. Serum level of YKL-40 does not predict advanced liver fibrosis in children with chronic hepatitis B Adv. Med. Sci. 2007 52 120 124 18217402

174. Pungpapong S. Nunes D.P. Krishna M. Nakhieh R. Chambers K. Ghabril M. Dickson R.C. Hughes C.B. Steers J. Nguyen J.H. Keaveny A.P. Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C Liver Transpl. 2008 14 1294 1302 10.1002/lt.21508 18756457

175. Mehta P. Ploutz-Snyder R. Nandi J. Rawlins S.R. Sanderson S.O. Levine R.A. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C Am. J. Gastroenterol 2008 103 928 936 10.1111/j.1572-0241.2007.01761.x 18371145

176. Schiavon L.L. Narciso-Schiavon J.L. Carvalho-Filho R.J. Sampaio J.P. Medina-Pestana J.O. Lanzoni V.P. Silva A.E. Ferraz M.L. Serum levels of YKL-40 and hyaluronic acid as non-invasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection J. Viral. Hepat. 2008 15 666 674 10.1111/j.1365-2893.2008.00992.x 18482283

177. Lee K.G. Seo Y.S. An H. Um S.H. Jung E.S. Keum B. Yim H.J. Jeen Y.T. Chun H.J. Kim C.D. Ryu H.S. Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B J. Gastroenterol. Hepatol. 2010 25 94 100 10.1111/j.1440-1746.2009.05953.x 19793171

178. Schiavon L.L. Carvalho-Filho R.J. Narciso-Schiavon J.L. Medina-Pestana J.O. Lanzoni V.P. Ferraz M.L. Silva A.E. YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection Scand. J. Gastroenterol. 2010 45 615 622 10.3109/00365521003637203 20163287

179. Recklies A.D. White C. Ling H. The chitinase 3-like protein human cartilage 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase-and protein kinase B-mediated signalling pathways Biochem. J. 2002 365 119 126 10.1042/BJ20020075 12071845 PMC1222662

180. Recklies A.D. Ling H. White C. Bernier S.M. Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes J. Biol. Chem. 2005 280 41213 41221 10.1074/jbc.M510146200 16234240

181. Ling H. Recklies A.D. The chitinase 3-like protein human cartilage glycoproein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumor necrosis factor-alpha Biochem. J. 2004 380 651 659 10.1042/BJ20040099 15015934 PMC1224214

182. Biosselier B. Marie Y. El Hallani S. Kaloshi G. Iershov A. Kavsan V. Psimaras D. Thillet J. Hoang-Xuan K. Delattre J.Y. Sanson M. No association of (−131C→G) variant of CHI3L1 gene with risk of glioblastoma and prognosis J. Neurooncol. 2009 94 169 172 10.1007/s11060-009-9817-4 19255724

183. Ober C. Tan Z. Sun Y. Possick J.D. Pan L. Nicolae R. Radford S. Parry R.R. Heinzmann A. Deichmann K.A. Lester L.A. Gern J.E. Lemanske R.F. Jr. Nicolae D.L. Elias J.A. Chupp G.L. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function N. Engl. J. Med. 2008 358 1682 1691 10.1056/NEJMoa0708801 18403759 PMC2629486

184. Zhao X. Tang R. Gao B. Shi Y. Zhou J. Guo S. Zhang J. Wang Y. Tang W. Meng J. Li S. Wang H. Ma G. Lin C. Xiao Y. Feng G. Lin Z. Zhu S. Xing Y. Sang H. St. Clair D. He L. Functional variants in the promoter region of Chitinase 3-Like 1 (CHI3L1) and susceptibility to schizophrenia Am. J. Hum. Genet. 2007 80 12 18 10.1086/510438 17160890 PMC1785314

185. Yang M.S. Morris D.W. Donohoe G. Kenny E. O’Dushalaine Schwaiger S. Nangle J.M. Clarke S. Scully P. Quinn J. Meagher D. Baldwin P. Crumlish N. O’Callaghan E. Waddington J.L. Gill M. Corvin A. Chitinase-3-like 1 (CHI3L1) gene and schizophrenia: genetic association and a potential functional mechanism Biol. Psychiatry 2008 64 98 103 10.1016/j.biopsych.2007.12.012 18281018

186. Ohi K. Hashimoto R. Yasuda Y. Yoshida T. Takahashi H. Iike N. Iwase M. Kamino K. Ishii R. Kazui H. Fukumoto M. Takamura H. Yamamori H. Azechi M. Ikezawa K. Tanimukai H. Tagami S. Morihara T. Okochi M. Yamada K. Numata S. Ikeda M. Tanaka T. Kudo T. Ueno S. Yoshikawa T. Ohmori T. Iwata N. Ozaki N. Takeda M. The chitinase 3-like 1 gene and schizophrenia: evidence from a multi-center case-control study and meta-analysis Schizophr. Res. 2010 116 126 132 10.1016/j.schres.2009.12.002 20051317

187. Srivastava S.K. Antal P. Gal J. Hullam G. Semsei A.F. Nagy G. Falus A. Buzas E.I. Lack of evidence for association of two functional SNPs of CHI3L1 gene (HC-gp39) with rheumatoid arthritis Rheumatol. Int. 2010 10.1007/s00296-010-1396-3 20300754

188. Kruit A. Grutters J.C. Ruven H.J.T. van Moorsel C.C. van den Bosch J.M. A CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker Respir. Med. 2007 101 1563 1571 10.1016/j.rmed.2006.12.006 17236752

189. Rathcke C.N. Holmkvist J. Jørgensen T. Borch-Johnsen K. Hansen T. Pedersen O.B. Vestergaard H. Variation in CHI3LI in relation to type 2 diabetes and related quantitative traits PloS One 2009 4 e5469 10.1371/journal.pone.0005469 19421404 PMC2674946

190. Rathcke C.N. Holmkvist J. Husmoen L.L. Hansen T. Pedersen O. Vestergaard H. Linneberg A. Association of polymorphisms of the CHI3L1 gene with asthma and atopy: a populations-based study of 6514 Danish adults PloS One 2009 4 e6106 10.1371/journal.pone.0006106 19568425 PMC2699472

191. Krause S.W. Rehli M. Kreutz M. Schwarzfisher L. Paulauski J.D. Andreesen R. Differential screening identifies genetic markers of monocyte to macrophage maturation J. Leukocyte Biol. 1996 60 540 545 8864140 10.1002/jlb.60.4.540

192. Hashimoto S. Suzuki T. Dong H.Y. Yamazaki N. Matsushima K. Serial analysis of gene expression in human monocytes and macrophages Blood 1999 94 837 844 10419873

193. Suzuki T. Hashimoto S. Toyoda N. Nagai S. Yamazaki N. Dong H.Y. Sakai J. Yamashita T. Nukiwa T. Matsushima K. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE Blood 2000 96 2584 2591 11001915

194. Benz K. Breit S. Lukoschek M. Mau H. Richter W. Molecular analysis of expansion, differentiation, and growth factor treatment of human chondrocytes identifies differentiation markers and growth-related genes Biochem. Biophys. Res. Commun. 2002 293 284 292 10.1016/S0006-291X(02)00223-1 12054597

195. Stokes D.G. Liu G. Coimbra I.B. Piera-Velazquez S. Crowl R.M. Jimenez S.A. Assessment of the gene expression profile of differentiated and dedifferentiated human fetal chondrocytes by microarray analysis Arthritis Rheum. 2002 46 404 419 10.1002/art.10106 11840443

196. Imabayashi H. Mori T. Gojo S. Kioyono T. Sugiyama T. Irie R. Isoga T. Hata J. Toyama Y. Umezawa A. Redifferentiation of dedifferentiated chondrocytes and chondrogenesis of human bone marrow stromal cells via chondrosphere formation with expression profiling by large-scale cDNA analysis Exp. Cell Res. 2003 288 35 50 10.1016/S0014-4827(03)00130-7 12878157

197. Junker N. Johansen J.S. Kristjansen P.E.G. Price P.A. Monoclonal antibody therapy against YKL-40 delays growth in glioblastoma xenografts American Association for Cancer Research Annual Meeting: Proceedings 2007 Los Angeles, CA, USA 14–18 April 2007 Abstract 4099

198. Pelloski C.E. Lin E. Zhang L. Yung W.K.A. Colman H. Liu J.-L. Woo S.Y. Heimberger A.B. Suki D. Prados M. Chang S. Barker F.G. III Fuller G.N. Aldape K.D. Prognostic associations of activated mitogen-activated protein kinase and akt pathways in glioblastoma Clin. Cancer Res. 2006 12 3935 3941 10.1158/1078-0432.CCR-05-2202 16818690

199. Lee C.G. Haartl D. Lee G.R. Koller B. Matsuura H. Da Silva C.A. Sohn M.H. Cohn L. Homer R.J. Kozhich A.A. Humbles A. Keaney J. Coyle A. Chupp G. Reed J. Flavell R.A. Elias J.A. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-12-induced tissue responses and apoposis J. Exp. Med. 2009 206 1149 1166 10.1084/jem.20081271 19414556 PMC2715037

200. Shao R. Hamel K. Petersen L. Cao Q.J. Arenas R.B. Bigelow C. Bentley B. Yan W. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis Oncogene 2009 28 4456 4468 10.1038/onc.2009.292 19767768 PMC2795793

201. Hillen F. Griffioen A.W. Tumor vascularization: sprouting angiogenesis and beyond Cancer Metastasis Rev. 2007 26 489 502 10.1007/s10555-007-9094-7 17717633 PMC2797856

202. Mizoguchi E. Chitinase 3-like-1 exacerbates intestinal inflammation by enhancing bacterial adhesion and invasion in colonic epithelial cells Gastroenterology 2006 130 398 411 10.1053/j.gastro.2005.12.007 16472595

203. Mizoguchi E. Mizoguchi A. Is the sugar always sweet in intestinal inflammation? Immunol. Res. 2007 37 47 60 10.1007/BF02686089 17496346

204. Kawada M. Chen C.C. Arihiro A. Nagatani K. Watanabe T. Mizoguchi E. Chitinase 3-like-1 enhances bacterial adhesion to colonic epithelial cells through the interaction with bacterial chitin-binding protein Lab. Invest. 2008 88 883 895 10.1038/labinvest.2008.47 18490894

205. Verheiden G.F.M. Rijnders A.W.M. Bos E. Coenen de-Roo C.J.J. van Staveren C.J. Miltenburg A.M.M. Meijerink J.H. Elewaut D. Keyser F. Veys E. Boots A.M.H. Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis Arthritis Rheum. 1997 40 1115 1125 10.1002/art.1780400616 9182922

206. Cope A.P. Patel S.D. Hall F. Congia M. Hubers H.A.J.M. Verheijden G.F. Boots A.M.H. Menon R. Trucco M. Rijnders A.V.M. Sønderstrup G. T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles Arthritis Rheum. 1999 42 1497 1507 10.1002/1529-0131(199907)42:7<1497::AID-ANR25>3.0.CO;2-# 10403279

207. Joosten L.A.B. Coenen de-Roo C.J.J. Helsen M.M.A. Lubberts E. Boots A.M.H. van der Berg W.B. Miltenburg A.M.M. Induction of tolerance with intranasal administration of human cartilage gp-39 in DBA/1 mice Arthritis Rheum. 2000 43 645 655 10.1002/1529-0131(200003)43:3<645::AID-ANR22>3.0.CO;2-O 10728759

208. Vos K. Miltenburg A.M.M. van Meijgaarden K.E. van den Heuvel M. Elferink D.G. van Galen P.J.M. van Hogezand R.A. van Vilet-Daskalopoulou E. Ottenhoff T.H.M. Breedveld F.C. Boots A.M.H. de Vries R.R.P. Cellular immune response to human cartilage glycoprotein-39 (HC gp-39)-derived peptides in rheumatoid arthritis and other inflammatory conditions Rheumatology 2000 39 1326 1331 10.1093/rheumatology/39.12.1326 11136874

209. Patil N.S. Hall F.C. Drover S. Spurrell D.R. Bos E. Cope A.P. Sonderstrup G. Mellins E.D. Autoantigenic HCgp39 epitopes are presented by the HLA-DM-dependent presentation pathway in human B cells J. Immunol. 2001 166 33 41 11123274 10.4049/jimmunol.166.1.33

210. Kavanaugh A. Genovese M. Baughman J. Kivitz A. Bulpitt K. Olsen N. Weisman M. Matteson E. Furst D. van Vollenhoven R. Anderson J. Cohen S. Wei N. Meijerink J. Jacobs C. Mocci S. Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial J. Rheumatol. 2003 30 449 454 12610799

211. Steenbakkers P.G.A. Baeten D. Rovers E. Veys E.M. Rijnders A.W.M. Meijerink J. Keyser F.D. Boots A.M.H. Localization of MHC Class II/human cartilage glycoprotein-39 complexes in synovia of rheumatoid arthritis patients using complex-specific monoclonal antibodies J. Immunol. 2003 170 5719 5727 12759455 10.4049/jimmunol.170.11.5719

212. Dickey B.F. Editorial Exoskeletons and exhalation N. Engl. J. Med. 2007 357 2082 2084 10.1056/NEJMe0706634 18003965

213. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing N. Engl. J. Med. 1986 315 1650 1659 10.1056/NEJM198612253152606 3537791

214. Balkwill F. Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001 357 539 545 10.1016/S0140-6736(00)04046-0 11229684

215. Balkwill F. Coussens L.M. An inflammatory link Nature 2004 431 405 406 10.1038/431405a 15385993

216. Balkwill F. Charles K.A. Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease Cancer Cell 2005 7 211 217 10.1016/j.ccr.2005.02.013 15766659

217. Coussens L.M. Werb Z. Inflammation and cancer Nature 2002 420 860 867 10.1038/nature01322 12490959 PMC2803035

218. DeClerck Y.A. Mercurio A.M. Stack M.S. Chapman H.A. Zutter M.M. Muschel R.J. Raz A. Matrisian L.M. Sloane B.F. Hendrix M.J. Coussens L. Padarathsingh M. Proteases, extracellular matrix, and cancer Am. J. Pathol. 2004 164 1131 1139 10.1016/S0002-9440(10)63200-2 15039201 PMC1615345

219. Moss S.F. Blaser M.J. Mechanisms of disease: inflammation and the origins of cancer Review Nature Clin. Pract. 2005 2 90 97 10.1038/ncponc0081 16264881

220. De Visser K.E. Eichten A. Coussens L.M. Paradoxical roles of the immune system during cancer development Nat. Rev. Cancer 2006 6 24 37 10.1038/nrc1782 16397525

221. Tlsty T.D. Coussens L.M. Tumor stroma and regulation of cancer development Annu. Rev. Pathol. Mech. Dis. 2006 1 119 150 10.1146/annurev.pathol.1.110304.100224 18039110

222. Lin W.W. Karin M. A cytokine–mediated link between immunity, inflammation, and cancer J. Clin. Invest. 2007 117 1175 1183 10.1172/JCI31537 17476347 PMC1857251

223. Gregoire M. Lieubeau B. The role of fibroblasts in tumor behavior Cancer Met. Rev. 1995 14 339 350 10.1007/BF00690602 8821094

224. Bissel M.J. Radisky D. Putting tumors in context Nat. Rev. Cancer 2001 1 46 54 10.1038/35094059 11900251 PMC2975572

225. Kenny P.A. Bissell M.J. Tumor reversion: correction of malignant behavior by microenvironmental cues Int. J. Cancer 2003 107 688 695 10.1002/ijc.11491 14566816 PMC2933180

226. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy Nat. Rev. Cancer. 2004 4 11 22 10.1038/nrc1252 14708024

227. Bigg H.F. Wait R. Rowan A.D. Cawston T.E. The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen fibril formation J. Biol. Chem. 2006 281 21082 21095 10.1074/jbc.M601153200 16704970

228. Jacques C. Recklies A.D. Levy A. Berenbaum F. HC-gp39 contributes to chondrocyte differentiation by inducing SOX9 and type II collagen expressions Osteoarthritis Cartilage. 2007 15 138 146 10.1016/j.joca.2006.07.003 16949314

229. Meyer M.F. Kreil G. Cells expressing the DG42 gene from early Xenopus embryos synthesize hyaluronan Proc. Natl. Acad. Sci. USA 1996 93 4543 4547 10.1073/pnas.93.10.4543 8643440 PMC39313

230. Semino C.E. Specht C.A. Raimondi A. Robbins P.W. Homologs of the Xenopus developmental gene DG42 are present in zebrafish and mouse and are involved in the synthesis of Nod-like chitin oligosaccharides during early embryogenesis Proc. Natl. Acad. Sci. USA 1996 93 4548 4553 10.1073/pnas.93.10.4548 8643441 PMC39314

231. Varki A. Does DG42 synthesize hyaluronan or chitin? A controversy about oligosaccharides in vertebrate development Proc. Natl. Acad. Sci. USA 1996 93 4523 4525 10.1073/pnas.93.10.4523 8643436 PMC39309

232. Toole B.P. Hyaluronan: from extracellular glue to pericellular cue Nat. Rev. Cancer 2004 4 528 539 10.1038/nrc1391 15229478

233. Fjeldstad K. Kolset S.O. Decreasing the metastatic potential in cancers – targeting the heparan sulfate proteoglycans Curr. Drug Targets 2005 6 665 682 10.2174/1389450054863662 16178800

234. Iwata T. Kuwajima M. Sukeno A. Ishimaru N. Hayashi Y. Wabitsch M. Mizusawa N. Itakura M. Yoshimoto K. YKL-40 secreted from adipose tissue inhibits degradation of type I collagen Biochem. Biophys. Res. Commun. 2009 388 511 516 10.1016/j.bbrc.2009.08.024 19666003

235. Locker G.Y. Hamilton S. Harris J. Jessup J.M. Kemeny N. MacDonald J.S. Somerfield M.R. Hayes D.F. Bast R.C. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer J. Clin. Oncol. 2006 24 5313 5327 10.1200/JCO.2006.08.2644 17060676

236. Hayes D.F. Bast R.C. Desch C.E. Fritsche H. Kemeny N.E. Jessup J.M. Locker G.Y. Macdonald J.S. Mennel R.G. Norton L. Ravdin P. Taube S. Winn R.J. Tumor Marker Utility Grading System: a framework to evaluate clinical utility of tumor markers J. Natl. Cancer Inst. 1996 88 1456 1466 10.1093/jnci/88.20.1456 8841020

237. Hayes D.F. Determination of clinical utility of tumor markers: a tumor marker utility grading system Recent Results Cancer Res. 1998 152 71 85 10.1007/978-3-642-45769-2_7 9928548

238. Werner M. Fraser C. Silverberg M. Clinical utility and validation of emerging biochemical markers for mammary adenocarcinoma Clin. Chem. 1993 39 2386 2396 8222250

239. Morrow D.A. de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers Circulation 2007 115 949 952 10.1161/CIRCULATIONAHA.106.683110 17325253

240. Freeman W.M. Bixler G.V. Brucklacher R.M. Lin C.M. Patel K.M. Vanguilder H.D. Lanoue K.F. Kimball S.R. Barber A.J. Antonetti D.A. Gardner T.W. Bronson S.K. A multistep validation process of biomarkers for preclinical drug development Pharmacogenomics J. 2009 10.1038/tpj.2009.60 19997081